NK 2023

Sept 26-29 | Oslo · Norway

Society for Natural Immunity · 20th meeting

differentiation

clinical trials

pregnancy

memory

cancer

virus

CONTENTS

LOCAL SCIENTIFIC & HOST COMMITTEE

Karl-Johan Malmberg, Oslo University Hospital, Oslo, Norway

Lise Kveberg, University of Oslo, Oslo, Norway

Erik Dissen, University of Oslo, Oslo, Norway

Marit Inngjerdingen, University of Oslo, Oslo, Norway

Yenan Bryceson, Karolinska Institutet, Stockholm, Sweden

Michael Daws, University of Oslo, Oslo, Norway

SNI COUNCIL MEMBERS

PRESIDENT: **Todd A. Fehniger**, Washington University School of Medicine, St. Louis, USA

PRESIDENT ELECT: **Mariapia Degli-Esposti**, Monash University, Victoria, Australia

PAST PRESIDENT: **Adelheid Cerwenka**, Heidelberg University, Mannheim, Germany

SCIENTIFIC REVIEW COMMITTEE

Adelheid Cerwenka, Heidelberg University, Mannheim, Germany

Aharon Freud, The Ohio State University, Columbus, USA

Barbara Kee, University of Chicago, USA

Carsten Watzl, Leibniz Research Center, Dortmund, Germany

Chiara Romagnani, Charité University and DRFZ Berlin, Germany

Eric Vivier, Centre d'Immunologie de Marseille-Luminy, Marseille, France

Hans-Gustaf Ljunggren, Karolinska Institutet, Stockholm, Sweden

Joseph Sun, Memorial Sloan Kettering Cancer Center, New York, USA

Katherine Hsu, Memorial Sloan Kettering Cancer Center, New York, USA

Katy Rezvani, MD Anderson Cancer Center, Houston, USA

Mariapia Degli-Esposti, Monash University, Victoria, Australia

Marcus Altfeld, Leibniz Institute for Virology, Hamburg, Germany

Megan Cooper, Washington University in St. Louis, USA

Nadia Guerra, Imperial College London, United Kingdom

Tim O'Sullivan, University of California Los Angeles, USA

Zhigang Tian, University of Science and Technology of China, Hefei, China

NK2023

GENERAL INFORMATION

VENUE

Scandic Holmenkollen Park Hotel
Kongeveien 26, 0787 Oslo, Norway
Telephone: +47 22 92 20 00

ROOMS

Plenary Session Room: Saga Hall
Poster Room: One floor down from Saga Hall you will find the poster rooms: Olav den Hellige, Gyda and Gunnhild, and heated tent in connection with Olav den Hellige.
Exhibits: Outside Saga Hall and in the mingling area in connection with the Poster Area.
Registration desk: By the main entrance, Hotel Foyer
Breakfast and lunch: Restaurant
Welcome reception: Restaurant
Gala dinner: Saga Hall

We have a couple of smaller meeting rooms available. Contact the registration desk for booking.
We are a big happy NK family and we have filled this venue with as many enthusiastic researchers as possible! Please leave no open seats between you and your neighbor during sessions and meals, welcome new colleagues to your tables, and spread out on all available coffee and food stations to make sure the logistics runs smoothly.

ABSTRACT PRESENTATIONS

All accepted abstracts, including those selected for oral presentations, will be presented as Posters. Use the poster number within the program schedule to locate posters in the Poster Area and in the Abstract Book.

The Abstract Book is available online at ***nk2023.org/abstractbook***
Username: nk2023
Password: k1ller!
For quick access, use the QR Code.

Selected Oral Abstract Presentations

Selected oral abstract presentations will take place in Saga Hall. Each abstract presenter will have 10 minutes total: 8 minutes for a formal presentation and 2 minutes for questions and answers.

Lightning Poster Presentations

There will be two Lightning Poster Sessions held during the meeting in Saga Hall. All Lightning Poster presenters will have 3 minutes (recommend max 3 slides) to present their work and 2 minutes for questions and answers.

INFORMATION FOR SPEAKERS/ ORAL PRESENTATIONS

Upload your presentations with the AV technician in Saga Hall on the day of your presentation at the following time points:

Tuesday:
07:30 – 08:30
12:00 – 12:30
15:15 – 15:30

Wednesday:
07:30 – 08:00
12:00 – 12:30

Thursday:
07:30 – 08:00
12:00 – 12:30

Friday:
07:30 – 08:30

Poster Presentations

Poster sessions will be Tuesday and Wednesday evenings in “Olav den Hellige” (below Saga Hall) and connected meeting rooms, including a heated tent in conjunction to “Olav den Hellige”.

Posters can be mounted from 10:00 am in the morning of the specified day and should be taken down directly after each poster session. Any posters not removed will be taken down and disposed by the staff.

Poster sessions will be held during the following times:

Poster Session 1
Tuesday, Sept 26th, 19:30 – 21:00
Poster numbers A1 – A130

Poster Session 2
Wednesday, Sept 27th, 20:00 – 21:30
Poster numbers B1 – B131

A listing of all poster presentations can be found on pages 24 - 38

MEET THE EDITOR SESSION

Thursday, September 28 12:15 – 13:15 (during lunch break)

Join us for an exclusive "Meet the Editor" session with Hannah Isles, associate editor at Science Immunology. This is a unique opportunity to gain insights into the world of scientific publishing, understand what editors look for in a manuscript, and learn how to make your research stand out. While our main aim is to engage young scientists and emerging group leaders, this session is open to all attendees. We believe in fostering a close-knit environment to facilitate meaningful interactions, and thus, we are limiting the session to 70 participants. Refreshments will be provided, ensuring that those who opt for this session won't miss out on a delightful meal. Whether you're a budding scientist eager to learn or an established researcher looking to understand the nuances of publishing, this session promises valuable takeaways for all. Register early to secure your spot! Scan QR-code for registration.

EXHIBITS

Please visit the exhibitors that will be present throughout the conference. You will find them located in the area outside Saga Hall as well as in the coffee break area one floor below.

The following companies are present with stands: BioLegend, Nordic BioSite, CellGenix, MaxCyte, Miltenyi Biotec, ScaleReady, and STEMCELL Technologies.

Exhibit hours

Tuesday, September 26
15:00 – 19:30 Exhibit open

Wednesday, September 27
08:00 – 17:30 Exhibit open
19.30 – 21:30 Exhibit open

Thursday, September 28
08:00 – 18:00 Exhibit open

Friday, September 29
08:30 – 13:00 Exhibit open

REGISTRATION

The registration desk is in the Conference Foyer. Please visit the registration desk upon arrival to collect your name badge, tickets and conference materials. You are required to wear your name badge during the whole meeting.

Registration Desk Hours

Monday Sept 25:	18:00 - 21:00
Tuesday Sept 26:	08:00 - 18:00
Wednesday Sept 27:	08:00 - 18:00
Thursday Sept 28:	08:00 - 18:00
Friday Sept 29:	08:00 - 13:00

TAXI AND TRANSPORTATION

Taxi can be ordered from the hotel reception.

T-bane #1 Bergkrystallen leaves every 15 min from Holmenkollen Station and takes you down to the city center in 25 min. For return, take the west bound train #1 towards Frognerseteren and exit at Holmenkollen Station. Make sure you have a valid ticket before you enter. There are various ways to buy a ticket, but the easiest is to use the "Ruter" app. **ruter.no/en/buying-tickets/sales-outlets/**

INTERNET

Wi-Fi is available for meeting attendees within the hotel meeting space.
Network: Scandic Meeting
Password: ATK83ymw

MEALS

Please make sure to wear your name badge for all meals. Please bring your special ticket for gala dinner and the prepaid ticket for the reception at the Fram museum.

All meals will be at the hotel except the reception at the Fram Museum on Wednesday, September 27 (ticket required). Participants not signed up for this event will need to organize dinner on their own. Dinner can be purchased in the restaurant at the hotel. Please contact the hotel desk for table reservation.

Breakfast is included for hotel guests and served from 7-10:00 am. Mealtimes and locations can be found within the detailed program schedule.

Coffee breaks. Coffee and refreshments are served downstairs below Saga Hall in the poster and mingling area, one floor up from Saga Hall, and if the weather is on our side also outdoors on the second floor.

Lunch is included for all participants and is served in the restaurant. In addition, we have some additional lunch bags available by the registration desk for participants who wants to go for a hike or wants to eat lunch somewhere else. These are distributed on a first come first served basis.
S**pecial exceptions:**

Participants at "Meet the Editor" session will be served lunch in Saga Hall.

- **Participants at the Board meeting will be served lunch in the meeting room Halfdan Svarte.**

Dinner: see "social events"

SOCIAL EVENTS

Welcome Reception

The Welcome Reception will take place on Tuesday, September 26th from 6:00 pm until 7:30 pm. The reception is included in the registration rate for all registered attendees and prepaid guests. Please wear your name tags to enter.

Visit to the Fram Museum – prepaid ticket required

The visit to the Fram Museum (**frammuseum.no**) will take place on Wednesday, September 27th from 17:30 until 20:00 and includes reception with food and drinks. This event is for participants that has registered and paid for this event and the ticket + drink tickets are included in your registration packets. Please show your ticket to enter the bus. Buses pick you up in the front of the hotel from 17:20. Final departure at 17:30. Please make sure to be precise as the buses will not wait for latecomers.

Bus departure from the Fram Museum at 19:30. Please go to the buses at 19:20. Arrival back at the hotel will be approximately 19:50.

Drink tickets for Welcome reception, Fram Museum Reception, and two poster sessions are included in the registration packets. For additional drinks, a cash bar will be available at all events. Credit cards are accepted.

Chess

Thursday Sept 28 at 18:00-18:45 in Olav den Hellige

Ever dreamt of challenging a chess grandmaster? Here's your golden opportunity! At NK2023 you can play simultaneous chess against the Grandmaster (FIDE 2593) Simen Agdestein. Not only is he a nine-time Norwegian champion (incl 2023), but he has also been the coach of Magnus Carlsen, the Norwegian chess player who is currently ranked #1 in the world.

This event is not just for the seasoned players with high ELO ratings but is open to enthusiasts of all levels. Spaces are limited, so make sure to sign up early and secure your spot on the chessboard. Embrace the challenge and make a move towards an unforgettable experience! Sign up with the QR code.

Gala Dinner

The Gala Dinner will take place on Thursday, September 28th at 20:00 in Saga Hall. As the space in Saga Hall is limited there is only available space for those participants that have signed up for this event during registration, and these participants have Gala Dinner tickets included in their registration materials. Please bring your ticket for entry.

It will be possible for those who have not signed up to join the party after dinner.

TRAVEL GRANT AWARD RECIPIENTS

Congratulation to the following students or postdoctoral fellows who were awarded a travel grant to attend the meeting!

Anucha Preechanukul, Mahidol University

Anzelika Rubina, Cardiff University

Everardo Hegewisch-Solloa, Columbia University Irving Medical Center

Giovanna Perinetti Casoni, Karolinska Institutet

Hanna Duàn, University of Helsinki

Inga Elisabeth Rødahl, Karolinska Institutet

Jake Myers, University of Minnesota

Jean De Lima, University of Basel

Jiarui Li, University of Science and Technology of China

Joey Li, University of California, Los Angeles

John Roy Lozada, University of Minnesota

Katja Srpan, Memorial Sloan Kettering Cancer Center

Malcolm Sim, University of Oxford

Michal Sheffer, Dana-Farber Cancer Institute

Ming Cheng, University of Science and Technology of China

Roseanna Kate Hare, University of Manchester

Samantha Barnes, University of Western Australia

Simon Grassmann, Memorial Sloan Kettering Cancer Center

Tasha Morrison, National Institutes of Health

Tomas Hofman, Heidelberg University

PROGRAM AT A GLANCE

Tuesday, September 26	
09:00 - 10:20	NK cells in the clinic I, Saga Hall
10:20 - 11:00	Coffee break (Foyer)
11:00 - 12:00	NK cells in the clinic II, Saga Hall
12:00 - 13:30	Lunch (Restaurant)
13:30 - 14:30	NK cells in the clinic III, Saga Hall
14:30 - 15:15	Roundtable discussion, Saga Hall
15:15 - 16:00	Coffee break (Foyer)
16:00 - 17:00	NK2023 Welcome and Keynote, Saga Hall
17:00 - 17:30	Lightning Session 1, Saga Hall
18:00 - 19:30	Welcome Reception (Restaurant)
19:30 - 21:00	Poster Session 1, A1-A130. Poster room
Wednesday, September 27	
08:30 - 10:00	Differentiation and Memory I, Saga Hall
10:00 - 10:30	Coffee break (Foyer)
10:30 - 12:00	Differentiation and Memory II, Saga Hall
12:00 - 13:30	Lunch (Restaurant)
13:30 - 15:30	Host Pathogen Interactions I, Saga Hall
15:00 - 15:30	Coffee break (Foyer)
15:30 - 16:40	Host Pathogen Interactions II, Saga Hall
16:40 - 17:10	Lightning Session 2, Saga Hall
17:30 - 20:00	Visit to Fram Museum (ticket required)
20:00 - 21:30	Poster Session 2, B1-B131. Poster room
Thursday, September 28	
08:30 - 10:00	Metabolism, Saga Hall
10:00 - 10:30	Coffee break (Foyer)
10:30 - 12:00	Tissue Resident Cells, Saga Hall
12:00 - 13:30	Lunch (Restaurant)
12:15 - 13:15	Meet the Editor session, including lunch for registered participants, Gyda and Gunhild
13:30 - 14:30	Cancer I, Saga Hall
14:30 - 15:30	Tissue Resident Cells II and Cancer II, Saga Hall
15:30 - 16:00	Coffee break (Foyer)
16:00 - 17:50	Cancer III, Saga Hall
20:00	Gala Dinner (only for signed up participants), Saga Hall
Friday, September 29	
09:00 - 10:30	Regulation and Specificity I, Saga Hall
10:30 - 11:00	Coffee break (Foyer)
11:00 - 12:20	Regulation and Specificity II, Saga Hall
12:20 - 12:30	Closing remarks, Saga Hall
12:30 - 14:00	Lunch (Restaurant)

MEETING WORKSHOP: NK CELLS IN THE CLINIC - Tuesday September 26 Saga Hall

NK CELLS IN THE CLINIC I

Moderators: Hans-Gustaf Ljunggren, Karolinska Institutet - Katy Rezvani, MD Anderson Cancer Center

09:00 - 09:20	Todd Fehniger, Washington University School of Medicine
09:20 - 09:40	Katy Rezvani, MD Anderson Cancer Center
09:40 - 10:00	Dean Lee, Nationwide Children's Hospital
10:00 - 10:20	Jeffrey Miller, University of Minnesota
10:20 - 11:00	Coffee break (Foyer)

NK CELLS IN THE CLINIC II

Moderators: Aharon Freud, The Ohio State University - Ebba Sohlberg, Karolinska Institutet

11:00 - 11:10	**A-102** Salim Khakoo, University of Southampton **Exportin-1 (XPO-1) as a target for natural killer cells in hepatocellular carcinoma**
11:10 - 11:20	**A-083** Michal Sheffer, Dana-Farber Cancer Institute **Cellular therapy of cytokine induced memory-like NK cells for the treatment of head and neck cancer**
11:20 - 11:30	**A-098** Erin Jeremy, The Ohio State University **The role of persistent AP-1 activation in NK cell exhaustion programming in AML**
11:30 - 11:40	**A-011** Sunil Acharya, MD Anderson Cancer Center **Generation and screening of various CD70 CAR NK cells identify the most effective construct against hematologic malignancies**
11:40 - 11:50	**A-079** Veronika Bachanova, University Of Minnesota **Allogeneic NK Cell Therapy for Lymphoma Revealed Cross-Talk with Adaptive T-Cell Immunity: Insights from Tumor Microenvironment Spatial Analysis**
11:50 - 12:00	**A-016** Jiri Eitler, Technische Universität Dresden **Dual targeting of PD-L1 and ErbB2 by CAR-NK cells enables specific elimination of solid tumor cells and overcomes immune escape via antigen loss**
12:00 - 13:30	Lunch (Restaurant)

NK CELLS IN THE CLINIC III

Moderators: Rizwan Romee, Dana-Farber Cancer Institute - Veronika Bachanova, University of Minnesota

13:30 - 13:50	Dan Kaufman, University of California San Diego
13:50 - 14:10	Ulrike Köhl, Fraunhofer Institut für Zelltherapie und Immunologie (IZI)
14:10 - 14:30	Eric Vivier, Centre d'Immunologie de Marseille-Luminy (CIML)

ROUNDTABLE DISCUSSION

14:30 - 15:15	PANEL: Rizwan Romee, Dana-Farber Cancer Institute Evren Alici, Karolinska Institutet, and Sarah Cooley, Sanofi
15:15 - 16:00	Closing of Workshop. Coffee and refreshments (Foyer)

Wifi: SCANDIC MEETING
Password: ATK83ymw

NK2023 WELCOME AND KEYNOTE

Moderators: Karl-Johan Malmberg, University of Oslo

16:00 - 16:10 Welcome

16:10 - 17:00 Keynote Lecture - Lewis Lanier, University of California, San Francisco

Natural Killer cells – a 4-decade Quest

LIGHTNING SESSION 1

Moderators: Erik Dissen, University of Oslo - Jakob Michaelsson, Karolinska Institutet

17:00 - 17:05 **A-059** Olli Dufva, University of Helsinki

Single-cell functional genomics of natural killer cell evasion in blood cancers

17:05 - 17:10 **A-064** Arman Bashirova, Leidos Biomedical Research

HLA class I signal peptide polymorphism: impact on HLA-E-mediated regulation of NK and T cells

17:10 - 17:15 **A-088** Sytse Piersma, Washington University in St Louis

HuR-dependent NK cell expansion mediate control of primary tumors without affecting clearance of tumor metastases

17:15 - 17:20 **A-081** Linnea Kristenson, University of Gothenburg

Deletion of the TMEM30A gene allows leukemic cell evasion of NK cell cytotoxicity

17:20 - 17:25 **A-087** Tobias Bexte, University Hospital Frankfurt

CRISPR/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-directed CAR-NK cells

17:25 - 17:30 **A-099** May Daher, MD Anderson Cancer Center

Crosstalk between NK cells and myeloid blasts leads to an epigenetic state of exhaustion

18:00 - 19:30 Welcome Reception (Restaurant)

19:30 - 21:00 Poster Session 1, A1-A130. Poster area

DIFFERENTIATION AND MEMORY I

Moderators: John O'Shea, National Institutes of Health - Ewa Sitnicka, Lund University

08:30 - 08:50	Andreas Diefenbach, Charité Berlin
08:50 - 09:10	Barbara Kee, University of Chicago
09:10 - 09:30	Joseph Sun, Memorial Sloan Kettering Cancer Center
09:30 - 09:40	**B-061** Sebastian Scheer, Luxembourg Institute of Health **The methyltransferase DOT1L controls NK cell activation and lineage integrity**
09:40 - 09:50	**B-068** Stephanie Jost, Duke University **Adaptive NK cells responses against antigenically distinct influenza viruses are partly mediated by HLA-E-stabilizing peptides derived from conserved antigens**
09:50 - 10:00	**B-079** Everardo Hegewisch-Solloa, Columbia University Irving Medical Center **A multifaceted deep dive into the NK cell developmental niche within human secondary lymphoid tissue**
10:00 - 10:30	Coffee break (Foyer)

DIFFERENTIATION AND MEMORY II

Moderators: Michael Caligiuri, City of Hope National Medical Center - Cynthia Dunbar, National Institutes of Health

10:30 - 10:50	Nicolas Serafini, Institut Pasteur
10:50 - 11:10	Chiara Romagnani, Charité University and DRFZ Berlin
11:10 - 11:30	Yenan Bryceson, Karolinska Institutet
11:30 - 11:40	**B-040** Helena Arellano Ballestero, University College London **Tumour-priming induces memory-like properties on NK cells: characterisation of the proteomic and receptor profile**
11:40 - 11:50	**B-036** Ming Cheng, University of Science and Technology of China **Transcription factor RORα promotes the formation and long-term maintenance of memory ILC1s**
11:50 - 12:00	**B-110** Markus Uhrberg, Heinrich-Heine University Düsseldorf **A novel human NK cell progenitor that originates in the thymus and generates NKG2A-KIR+ NK cells**
12:00 - 13:30	Lunch (Restaurant)

HOST PATHOGEN INTERACTIONS I

Moderators: Dimitra Peppa, University College London - Quirin Hammer, Karolinska Institutet

13:30 - 13:50	Mariapia Degli-Eposti, Monash University
13:50 - 14:10	Catherine Blish, Stanford University
14:10 - 14:30	Stephen Waggoner, Cincinnati Children's Hospital Medical Center
14:30 - 14:40	**B-082** Simon Grassman, Memorial Sloan Kettering Cancer Center **Early antigen-receptor signaling primes NK cells for optimal cytokine signaling during infection**
14:40 - 14:50	**B-074** Jesse Bruijnesteijn , Biomedical Primate Research Centre **Chromosomal rearrangements in the KIR gene cluster as evolutionary strategy to fight fast evolving pathogens**
14:50 - 15:00	**A-101** Wilfredo Garcia-Beltran, Ragon Institute of Mass General, MIT and Harvard SARS-CoV-2 evades NK-cell immunity by ORF6-mediated shedding of NKG2D ligands, uncovering a novel immunotherapeutic target conserved among sarbecoviruses
15:00 - 15:30	Coffee break (Foyer)

HOST PATHOGEN INTERACTIONS II

Moderators: Marcus Altfeld, Leibniz Institute for Virology - Clair Gardiner, Trinity College Dublin

15:30 - 15:50 Mary Carrington, Frederick National Laboratory for Cancer Research

15:50 - 16:10 Marit Inngjerdingen, University of Oslo

16:10 - 16:20 **B-057** Patrick Ross, San Diego Biomedical Research Institute
Leveraging MINFLUX Nanoscopy to Understand NK Cell Immunological Synapse Structure and Dynamics

16:20 - 16:30 **B-071** Anzelika Rubina, Cardiff University
Human cytomegalovirus genes UL148 and UL148D inhibit NK cell function by promoting surface expression of inhibitory ligands via impairment of ADAM17

16:30 - 16:40 **B-032** Jean De Lima, University of Basel
Redefining the lung immune cell network: crosstalk between HIF-1a+ CD4 T cells and NK cells during influenza infection

LIGHTNING SESSION 2

Moderators: Amir Horowitz, Mount Sinai - Janine Melsen, Leiden University Medical Center

16:40 - 16:45 **B-113** Giovanna Perinetti Casoni, Karolinska Institutet
DEF6 promotes canonical CD56dim NK cell survival and cytotoxicity

16:45 - 16:50 **B-090** Adriana Mujal, Memorial Sloan Kettering Cancer Center
Tissue-specific determinants of adaptive NK cell responses

16:50 - 16:55 **B-035** Tomas Hofman, Heidelberg University
IFNg- and sialic acid pathways drive melanoma resistance via selective inhibition of NK cell subsets

16:55 - 17:00 **B-020** Nicole Wild, Karolinska Institutet
Characterisation of organ-specific tissue-resident NK cells across human tissues

17:00 - 17:05 **B-075** Janine Melsen, Leiden University Medical Center
Deciphering human NK cell development using high-dimensional phenotyping and imaging: tonsil versus thymus

17:05 - 17:10 **B-080** Roseanna Hare, University of Manchester
Ligand mobility is necessary for TIGIT to assemble into nanoscale clusters at immune synapses

17:30 - 20:00 Visit to Fram Museum (ticket required)

20:00 - 21:30 Poster Session 2, B1-B131. Poster area

MEETING PROGRAM - Thursday September 28

Saga Hall

METABOLISM
Moderators: Jeanette Boudreau, Dalhousie University - Fredrik Berg Thorén, University of Gothenburg

08:30 - 08:50	Thierry Walzer, Inserm, Lyon
08:50 - 09:10	Cristhiane Favero De Aguiar, Trinity College Dublin
09:10 - 09:30	Jeanette Boudreau, Dalhousie University
09:30 - 09:40	**B-119** Joey Li, University of California Los Angeles **MEF2C is a critical regulator of human NK cell metabolism**
09:40 - 09:50	**B-116** Sam Sheppard, Imperial College London **Fatty acid metabolism promotes natural killer cell cytotoxicity and anti-tumor function**
09:50 - 10:00	**A-089** Katja Srpan, Memorial Sloan Kettering Cancer Center **PD-L1 ligation enhances NK cell cytotoxicity by inducing metabolic shift**
10:00 - 10:30	Coffee break (Foyer)

TISSUE RESIDENT CELLS
Moderators: Ashley Moffett, University of Cambridge - Nicole Marquardt, Karolinska Institutet

10:30 - 10:50	Jenny Mjösberg, Karolinska Institutet
10:50 - 11:10	Francesco Colucci, University of Cambridge
11:10 - 11:30	Niklas Björkström, Karolinska Institutet
11:30 - 11:50	Marco Colonna, Washington University School of Medicine
12:00 - 13:30	Lunch (Restaurant)
12:15 - 13:30	Dr. Hannah Isles, Associate Editor Science Immunology **Meet the Editor session, including lunch for registered participants - in meeting rooms Gyda and Gunhild**

CANCER I
Moderators: Aura Muntasell, Hospital del Mar Medical Research Institute - Sytse Piersma, Washington University in St Louis

13:30 - 13:50	Katharine Hsu, Memorial Sloan Kettering Cancer Center
13:50 - 14:10	Bethany Mundy-Bosse, The Ohio State University
14:10 - 14:30	Frank Cichocki, University of Minnesota

TISSUE RESIDENT CELLS II AND CANCER II
Moderators: Salim Khakoo, University of Southampton - Victoria Male, Imperial College London

14:30 - 14:40	**B-045** Hui Peng, University of Science and Technology of China **Development and function of liver-resident NK cells/ILC1s: from fetal to adult life**
14:40 - 14:50	**B-019** Inga Elisabeth Rødahl. Karolinska Institutet **Tracking tissue-dependent gene expression in fetal NK cells at the clonal level**
14:50 - 15:00	**B-064** Aline Pfefferle, Karolinska Institutet **A Temporal Transcriptional Reference Map of Human Natural Killer Cells**

Wifi: SCANDIC MEETING
Password: ATK83ymw

15:00 - 15:10 **A-021** Samantha Barnes, University of Western Australia
Transcriptional profiling of highly functional natural killer cells reveals novel drivers of anti-cancer immunity

15:10 - 15:20 **A-052** John Roy Lozada, University of Minnesota
A Single-Cell Transcriptomic Atlas of Natural Killer (NK) Cells Across Solid Tumors: A Roadmap for Enhancing NK Cell Immunotherapies

15:20 - 15:30 **B-028** Clara Serger, University Hospital Basel
Characterization of the chromatin and transcriptional landscapes of intratumoral NK cells using single cell multiomics

15:30 - 16:00 Coffee break (Foyer)

CANCER III
Moderators: Fernando Guimaraes, The University Of Queensland - Philippa Kennedy, University of Minnesota

16:00 - 16:20 David Raulet, University Of California, Berkeley

16:20 - 16:40 Satu Mustjoki, University of Helsinki

16:40 - 17:00 Amir Horowitz, Mount Sinai

17:00 - 17:20 Adelheid Cerwenka, Heidelberg University, Medical Faculty Mannheim

17:20 - 17:30 **A-070** Hanna Duàn, University of Helsinki
Acute myeloid leukemia patients trigger distinct activation patterns in expanded NK cells upon treatment

17:30 - 17:40 **B-049** Jake Myers, University of Minnesota
Exhaustion induces transcriptional and epigenetic alterations in human NK cells that weaken NK cell activation through reduced ERK1/2 signaling and cell migration

17:40 - 17:50 **B-008** Dagmar Gotthardt, University of Veterinary Medicine Vienna
NK cell senescence as barrier to malignant transformation

20:00 Gala Dinner (only for signed up participants), Saga Hall

REGULATION AND SPECIFICITY I

Moderators: Petter Höglund, Karolinska Institutet - Ana Stojanovic, Heidelberg University MI3

09:00 - 09:20	Nicholas Huntington, Monash University
09:20 - 09:40	Carsten Watzl, IfADo
09:40 - 10:00	Wayne Yokoyama, Washington University in St. Louis
10:00 - 10:10	**B-089** Tasha Morrison, National Institutes of Health **Essential role of Ugcg for natural killer cell homeostasis and cytolytic function**
10:10 - 10:20	**B-048** Malcolm Sim, University of Oxford **Activating KIR are not weak but peptide specific**
10:20 - 10:30	**B-024** Samantha Borys, Brown University **NK cells regulate CD8+ T cell homeostasis in the murine submandibular glands**
10:30 - 11:00	Coffee break (Foyer)

REGULATION AND SPECIFICITY II

Moderators: Eric Long, National Institute of Allergy and Infectious Diseases - Melissa Berrien-Elliot, Washington University School of Medicine

11:00 - 11:20	Jordan Orange, Columbia University
11:20 - 11:40	Emily Mace, Columbia University Irving Medical Center
11:40 - 12:00	Tim O'Sullivan, University of California Los Angeles
12:00 - 12:20	Daniel Davis, Imperial College London
12:20 - 12:30	Closing remarks
12:30 - 14:00	Lunch (Restaurant)

PREVIOUS NK MEETINGS

1st	1992	St. Petersburg, FL, USA
2nd	1994	Taormina, ME, Italy
3rd	1995	Channel Islands, Oxnard, CA, USA
4th	1997	Helsinki, Finland
5th	1998	Warrenton, VA, USA
6th	2000	Marseille, France
7th	2002	San Juan, Puerto Rico
8th	2004	Amsterdam, The Netherlands
9th	2005	Kauai, HI, USA
10th	2007	Cambridge, England
11th	2008	Perth, Australia
12th	2010	Dubrovnik, Croatia
13th	2012	Asilomar, CA, USA
14th	2013	Heidelberg, Germany
15th	2015	Montebello, QC, Canada
16th	2016	Taormina, ME, Italy
17th	2018	San Antonio, TX, USA
18th	2019	Luxembourg
19th	2022	Bonita Springs, FL, USA

SPONSOR INFORMATION

We would like to thank the following sponsors for the support to NK2023

GOLD SPONSORS

fatetherapeutics.com

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens, and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA.

sanofi.com

vycellix.com

Vycellix, Inc. is advancing next-generation, allogeneic natural killer cell (NK cell)-based cancer therapeutics, leveraging its transformational VY-UC™ universal cell platform technology. The VY-UC approach to engineering "off-the-shelf" NK cells is designed to be cost-efficient, scalable, and ensure the functional integrity of donor-derived NK cells for optimized performance, persistence, and avoidance of immune rejection. NK cells transduced with single-step VY-UC technology are truly immune-privileged (100% abrogation of cellular immune response) due to proprietary CD45-engager engineering, which has been shown to prevent immunological synapse and obviate the need for immune-suppressive regimens. With operations in Tampa, Florida, USA and Stockholm, Sweden, the Company's mission is to develop and commercialize a broad pipeline of best-in-class, allogeneic NK cell therapeutics for the treatment of solid tumors and hematological malignancies.

SILVER SPONSORS

maxcyte.com

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. MaxCyte builds best-in-class technology designed to facilitate complex engineering of a wide variety of cells and to drive the rapidly expanding cell therapy market forward. For over 20 years, MaxCyte has been perfecting the art of cell-engineering and venturing beyond today's process to innovate tomorrow's solutions. Let's Build Better Cells Together.

scaleready.com

ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. Bringing together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing, ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry. Our platform includes G-Rex® cell culture technology, the Lovo and Cue cell processing systems, and a wide range of GMP proteins, reagents, media, and gene editing technologies.

BRONZE SPONSORS

affimed.com

At Affimed, we focus on using the body's own immune system to fight cancer by developing therapies using our using our proprietary ROCK® platform to generate bispecific innate cell engagers (ICE®), which can be tailored to hematological and solid tumor targets. The ICE® molecules form a connection with the CD16A receptor on innate immune cells (NK cells and macrophages), as well as a specific target on cancer cells. Upon establishing this bond, the immune cells are activated and kill tumor cells. Our innovative approach has made us the first company to have a clinical-stage ICE®.

cellgenix.com

Sartorius CellGenix is a leading global supplier of high quality raw materials for the expanding cell and gene therapy market. We develop, manufacture and market preclinical and GMP cytokines along with GMP serum-free media for further manufacturing of ATMPs. Our products are used by academia and industry partners in preclinical development, clinical trials, and commercial manufacturing throughout the world. With +25 years of experience, we are experts in the GMP manufacturing of raw materials for the cell and gene therapy space. By offering expert technical and regulatory support we can help simplify raw material qualification and validation efforts.

Cellmover

cellmover.com

Cellmover is a Norwegian start-up company developing novel checkpoint inhibitors to broadly protect T cells and NK cells from inhibitory signaling by tumors, by targeting intracellular inhibitory signaling hubs for broad shielding of inhibitory input. The technology makes use of unique peptides and nanobodies designed to function inside T and NK cells, coupled to unique targeting entities.

ImmuneBridge

immunebridge.com

ImmuneBridge's mission is to make curative immunotherapies accessible to all by accessing the solutions banked within nature's (innate) diversity. We're developing allo-NKs for cancer. Our proprietary technology expands cord blood-derived immune stem cells while preserving their multipotency, offering a diverse yet consistent cellular source. Our Cellular Discovery Platform supports detailed screening and phenotype selection from a broad spectrum of innate immune genetic backgrounds, in a translatable and scalable system. We're based in the Mission District of San Francisco. We welcome like-minded collaborators who share the vision of making potent, persistent and tunable NK products to address clinical needs.

innate pharma

innate-pharma.com

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients.Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform. Headquartered in Marseille, France, Innate's portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.

Miltenyi Biotec

miltenyibiotec.com

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies enable solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Today, Miltenyi Biotec has more than 4,700 employees in 23 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health.

oncopeptides

oncopeptides.com

Oncopeptides is a global biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. Our vision is to bring hope to patients through passionate people, innovative science and transformative medicines. We are science driven, entrepreneurial, and committed to bringing innovation to patients with diseases where there is a clear unmet need. Oncopeptides first product Pepaxti is a Peptide Drug Conjugate (PDC), our pipeline also includes additional candidates built on the PDC platform and the Small Polypeptide based Killer Engagers (SPiKE) platform. The company headquarters and its modern pre-clinical drug development facility are both situated in Stockholm, Sweden.

XNK THERAPEUTICS

xnktherapeutics.com

XNK Therapeutics is a clinical-stage immunotherapy company focused on bringing more effective treatments to cancer patients. The company is at the forefront of autologous NK cell-based cell therapy development with a proprietary technology platform and a pipeline spanning hematological malignancies and solid tumors. Our autologous treatment allows for multiple administrations without the need for immunosuppressive pre-treatment. Studies are ongoing in multiple myeloma, AML, urothelial cancer and hepatocellular carcinoma. These are performed in collaboration with global pharma companies and strong institutions such as MD Anderson Cancer Center and the Karolinska University Hospital.

zelluna IMMUNOTHERAPY

zelluna.com

Zelluna Immunotherapy is a privately held biotech company developing a novel allogeneic TCR-NK cell therapy platform for the treatment of solid cancers. The TCR-NK technology offers a combination of adaptive and innate activity and may overcome some of the mechanisms used by tumors to escape T cell recognition and has the potential to drive durable clinical responses against heterogeneous tumors. The company has built in-house TCR discovery and engineering capabilities, a proprietary TCR-NK manufacturing process and the company's pipeline contains products targeting antigens expressed across a broad range of solid cancers – MAGE-A4 (lead), KK-LC-1 and PRAME.

ACADEMIC PARTNERS

ki.se/en/research/nextgennk

NextGenNK is a Competence Center for the development of next generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. The Center was launched in 2020, and is jointly funded by Vinnova, KI, and the Industrial partners.

prima.uio.no/english

PRIMA is a Center of Excellence in Precision Immunotherapy funded by the Research Council of Norway. The Centre is hosted by the University of Oslo, Institute of Clinical Medicine, with Oslo University Hospital as partner. The vision of PRIMA is to develop the next generation of precision immunotherapy.

onlinelibrary.wiley.com/journal/13653083

The Scandinavian Journal of Immunology is published on behalf of the Scandinavian Foundation for Immunology and is the official journal of the Scandinavian Society for Immunology (SSI). The SSI is an umbrella society for the national societies of Denmark, Finland, Iceland, Norway and Sweden. The Scandinavian Journal of Immunology is a peer-reviewed international journal that publishes original articles and reviews on all aspects of basic, translational and clinical immunology. The journal aims to provide high quality service to authors, and high quality articles for readers. The journal accepts for publication material from investigators all over the world, which makes a significant contribution to basic, translational and clinical immunology.

Supported by UiO:Life Science

uio.no/english/research/strategic-research-areas/life-science/

Life sciences represent the largest priority area of the University of Oslo. We develop new knowledge in the life sciences by combining the most cutting-edge areas of research in academic disciplines such as medicine and biology with new, advanced methods of analysis from disciplines such as mathematics, chemistry, pharmacology, physics and computer science. We also use social science and humanities disciplines to understand life sciences from an overall societal perspective. By working across disciplines we can obtain new, groundbreaking answers to questions for which a single approach and one subject discipline alone brings us no closer to solutions.

OTHER SPONSORS

STEMCELL™ TECHNOLOGIES

stemcell.com

Driven by science and a passion for quality, STEMCELL Technologies provides cell isolation products, specialized cell culture media, primary cells, and supporting reagents for immunology research. Our popular EasySep™ platform is the fastest and easiest cell separation technology available for the isolation of untouched, highly purified, functional human and mouse immune cells including NK cells. Visit us at the STEMCELL Technologies booth to explore our complete workflow for NK cell research, from sample sourcing to NK cell expansion to downstream analysis.

Nordic BioSite

nordicbiosite.com

Millions of products for your research. Discover an extensive product range within numerous research areas. Search among more than 5.700.000 products for life science research and read about trends in biological sciences, technical tips and suggestions, and much more in our Life Science Blog.

BioLegend®
Enabling Legendary Discovery™

biolegend.com

BioLegend creates world-class, cutting-edge antibodies and reagents across a diverse set of applications—from flow cytometry to immunoassays. Founded by scientists, for scientists—we aren't just making a difference, we are different. We're accelerating research and discovery by providing high-quality, purpose-driven products at an outstanding value. With over 29,000 trusted reagents and a dedicated team to create custom solutions, there's nothing our expertise doesn't cover.

POSTER PRESENTATIONS

POSTER	CONTENT	AUTHOR	REPRESENTING
A-001	Mucosal NK subsets contribute to the efficacy of HIV vaccine candidate in macaques	Mohammad Arif Rahman	Animal Model and Retroviral Vaccine Section, National Cancer Institute
A-002	Controlling HCMV Through ADCC-inducing Immunotherapies	Hannah Preston	Cardiff University
A-003	Investigation of microenvironment-driven changes in group 1 ILCs during cancerogenesis	Robin Schenk	Department of Internal Medicine II, Technical University of Munich
A-004	PRMT5 mediates DNA damage response in Extra-Nodal NK/T-cell Lymphoma (ENKTL)	Youssef Youssef	The Ohio State University, Department of internal Medicine, Division of Hematology, College of Medicine
A-005	Engineering natural killer cells for improved function in tumor environments by disrupting the AhR-ARNT-HIF1α signaling node.	Marcelo Pereira	Nationwide Children's Hospital, Center for Childhood Cancer Research
A-006	Pre-clinical evaluation and first-in-dog clinical trials of intravenous infusion of PBMC-expanded adoptive NK cell therapy in dogs with cancer	Aryana Razmara	Department of Surgery, UC Davis School of Medicine
A-007	Optimizing scale-up process of differentiating iPSCs to iNKs in a clinically relevant manner	Sophia Borate	Karolinska Institutet
A-008	The role of natural killer cells during the pathogenesis of childhood arthritis	Oliver Knight	Innate Immunity, Deutsches Rheuma-Forschungszentrum (DRFZ), an Institute of the Leibniz Association
A-009	Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells using Feeder cell or Non-feeder cell Expansion Systems	Dongfang Liu	Rutgers University
A-010	An Optimized Pipeline for Primary Natural Killer Cell Engineering Using Lentiviral Vector	Yi Jun Lan	Academia Sinica
A-011	Generation and screening of various CD70 CAR NK cells identify the most effective construct against hematologic malignancies	Sunil Acharya	MD Anderson Cancer Center
A-012	Accumulation of NK cells with a tissue-resident phenotype in human lung tumors	Demi Brownlie	Karolinska Institutet
A-013	Hijacking upregulated E-selectin and reduced SDF-1α in the AML niche to rewire NK cells to the leukemia and thereby improve the efficacy of adoptive cellular cancer immunotherapy	Laura Sanz Ortega	Department of Medicine, Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet
A-014	S095029: a novel clinical-stage Fc-silenced NKG2A-blocking antibody for cancer immunotherapy	Bruno Laugel	Institut de Recherche Servier
A-015	HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells	Britta Zecher	Leibniz Institute of Virology
A-016	Dual targeting of PD-L1 and ErbB2 by CAR-NK cells enables specific elimination of solid tumor cells and overcomes immune escape via antigen loss	Jiri Eitler	Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
A-017	Increasing the persistence and efficiency of Chimeric Antigen Receptor - NK cells	Katharina Ruppel	Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany
A-018	Targeting T-Cell Lymphoma Using CD70-Directed CAR-NK Cells and CRISPR/Cas9-Mediated Checkpoint Blockade	Hind Rafei	The University of Texas MD Anderson Cancer Center

POSTER	CONTENT	AUTHOR	REPRESENTING
A-019	Optimizing T-cell receptor engineering of primary NK-cells with soluble IL-15 to therapeutically target tumors and prolong survival	Els Van Hees	Leiden University Medical Centre
A-020	CAR-mediated retargeting of NK cells overcomes tumor immune escape based on ICAM-1 downregulation	Wiebke Rackwitz	Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
A-021	Transcriptional profiling of highly functional natural killer cells reveals novel drivers of anti-cancer immunity	Samantha Barnes	University Of Western Australia
A-022	Engineering chimeric antigen receptors with NK-cell activating domainsto improve the efficacy of tumor-targeted NK cells	Maren Prüfer	Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy
A-023	KoRV-pseudotyping of lentiviruses enables fast and streamlined generation of engineered NK cells for immunotherapy	Alexander Renner	Fraunhofer Institute for Cellular Therapy and Immunology (IZI)
A-024	Empowering NK cell immunotherapy against Multiple Myeloma: CAR engineering and receptor knockdown for enhanced specificity and NK cell survival	Katharina Schindler	Fraunhofer Institute Leipzig
A-025	Heightened metabolic responses in NK cells from patients with neuroblastoma suggests increased potential for immunotherapy	Clair Gardiner	Trinity College Dublin
A-026	Dissecting tumor sensitivity to NK cell-mediated lysis	Emilie Narni-Mancinelli	Ciml
A-027	Validation of ICH Q2 compliant 13-color flow cytometry-based Quality Control panels for the characterization of CAR-NK cell products	Juliane Schlueter	University Hospital Frankfurt, Department of Pediatrics, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Goethe University Frankfurt
A-028	Integrin α as a potential checkpoint of natural killer cell	Yu Zhang	Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China
A-029	Combinatorial immunotherapy of tetravalent bispecific AFM13 and AB-101 NK cell product confers tumor growth control in vivo	Jens Pahl	Affimed GmbH
A-030	Natural killer cells in mutant calreticulin-driven myeloproliferative neoplasms	Agnieszka Witalisz-Siepracka	Division Pharmacology, Karl Landsteiner University of Health Sciences
A-031	Fasting reshapes NK cell metabolism to improve anti-tumor responses	Rebecca Delconte	Memorial Sloan Kettering Cancer Center
A-032	Redefining the lung immune cell network: crosstalk between HIF-1a+ CD4 T cells and NK cells during influenza infection	Jean De Lima	University of Basel
A-033	The immune modulating properties of Oncolytic viruses encoding TriKEs.	Aparna Ponnurangam	ViraTherapeutics
A-034	Role of autoreactive Natural Killer cells in the pathogenesis of Primary Biliary Cholangitis	Sara Franzese	University Of Milan
A-035	Investigating natural killer cell function in brain metastasis using single-cell RNA sequencing and imaging mass cytometry	Timothy McMullen	University Of California, Irvine
A-036	Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout for cancer therapy	Seung-Hwan Lee	University of Ottawa

POSTER	CONTENT	AUTHOR	REPRESENTING
A-037	Severity of COVID-19 and activating natural killer cell immunoglobulin-like receptors	Lourdes Gimeno Arias	Immunology Service, Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), and Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.
A-038	Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers	Inmaculada Ruiz-Lorente	Immunology Service. Hospial Clinico Universitario Virgen de la Arrixaca and Instituto Murciano de Investigación Biosanitaria (imib). Murcia, Spain.
A-039	NK cell-monocyte crosstalk underlies NK cell activation and dysfunction in severe COVID-19	Madeline Lee	Stanford University
A-040	Antibody targeting of soluble MHC-class-I-related molecule augments natural killer cell cytotoxicity by restoring NKG2D in multiple myeloma	Hyunsoo Cho	Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine
A-041	Functional and transcriptional investigation of NK responses in COVID-19 breakthrough infections	Leslie Chan	Stanford University
A-042	Differential dependency of CD19 chimeric antigen receptor (CAR)-T (TX019) and CD19- (CAR) natural killer (NK) cells (NKX019) on CD58 loss in Acute Lymphoblastic Leukemia (ALL)	Carmel Chan	Nkarta Therapeutics
A-043	Chem_NK: Chemically primed natural killer cells with potent anti-tumor immunity	Kyung-Soon Park	CHA University
A-044	Assessing in vivo expansion and persistence of allogeneic NK cell therapies using HLA-specific flow cytometry and NGS-based molecular chimerism.	Robin Nakkula	Nationwide Children's Hosptial AW Research Institute
A-045	Expansion of CD151+ NK cell subset correlates with COVID-19 severity.	Ainhoa Amarilla-Irusta	Immunopathology Group, Biocruces Bizkaia Health Research Institute
A-046	Following autologous hematopoietic stem cell transplantation immature, activated, inhibitory KIR expressing and CD9+CD151+ decidual-like NK cell subsets are expanded in children with cancer	Gabirel Astarloa-Pando	Immunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
A-047	Patient-derived pancreatic cancer tumor organoids: a more clinically relevant and efficient way to evaluate the efficacy of CD70-targeting CAR NK cells	Laura Gehrcken	Center for Oncological Research, Integrated Precision and Personalized Oncology Network (IPPON), University of Antwerp
A-048	Bispecific killer cell engagers efficiently redirect effector lymphocytes engineered with an NKG2D-based CAR to PD-L1-positive cancer cells	Jordi Pfeifer Serrahima	Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy
A-049	Transcriptional repurposing of Natural Killer cells: a novel opportunity to enhance immunotherapy efficacy in Triple-Negative Breast Cancer	Francesca Reggiani	AUSL-IRCCS of Reggio Emilia
A-050	Improving Cell Culture Conditions for the GMP-compatible NK Cell Expansion	Ann-Kathrin Kistenmacher	Fraunhofer Institute for Cell Therapy and Immunology (IZI), Department for Cell and Gene Therapy Development
A-051	Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment	Tim Dalessandri	XNK Therapeutics
A-052	A Single-Cell Transcriptomic Atlas of Natural Killer (NK) Cells Across Solid Tumors: A Roadmap for Enhancing NK Cell Immunotherapies	John Roy Lozada	University Of Minnesota
A-053	Overcoming Suppression of NK cell Function in Advanced Prostate Cancer with a Novel PSMA Targeting TriKE	Gwen Phung	University of Minnesota
A-054	NK cell immunotypes associated with poor prognosis in end stage liver disease.	Christopher Maucourant	Karolinska Institutet

POSTER	CONTENT	AUTHOR	REPRESENTING
A-055	Osteosarcoma develops resistance against anti-HER2 primary CAR NK cells by upregulation of NF-κB signaling as a response to TNF-α secretion	Colin Maguire	Nationwide Children's Hospital Center for Childhood Cancer
A-056	Exploring exhaustion- How to overcome NK cell dysfunction for a durable anti-tumoral response?	Sophie-Christin Linkenbach	TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
A-057	Boosting Natural Killer cell immunity: improving a future without treatment for CML patients.	Ayla Grotens	Department of Hematology, Radboud university medical center
A-058	Optimising perfusion parameters using Quality by Design for the intensified production of CAR T cells in a single-use automated stirred-tank bioreactor	Julia Hengst	Sartorius Stedim Biotech GmbH
A-059	Single-cell functional genomics of natural killer cell evasion in blood cancers	Olli Dufva	University Of Helsinki
A-060	Ex vivo Expansion of Autologous Natural Killer Cells for Systemic Treatment of Advanced Bladder Cancer	Amineh Ghaderi	XNKTherapeutics
A-061	Upscaled manufacturing of an off-the-shelf stem cell-derived natural killer cell therapy for cancer	Laura Hooijmaijers	Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center
A-062	A B7H3-Targeting Tri-specific Killer Engager (TriKE®) Enhances Natural Killer Cell Effector Functions in the Solid Tumor Microenvironment of Head and Neck Carcinomas	Melissa Khaw	Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota
A-063	The evolution and role of Natural Killer (NK) cells during acute HIV-1 infection with different HIV-1 subtypes	Aljawharah Alrubayyi	Nuffield Department of Clinical Medicine, Centre for Immuno-Oncology, University of Oxford, United Kingdom
A-064	HLA class I signal peptide polymorphism: impact on HLA-E-mediated regulation of NK and T cells.	Arman Bashirova	Frederick National Laboratory For Cancer Research
A-065	Resistance to oxidative stress supports superior cytotoxicity of pre-activated human NK cells in hypoxia	Martin Felices	University Of Minnesota
A-066	SENTI-401, a multi-armed, logic gated CAR-NK cell candidate therapy for the precise targeting of CEACAM5-expressing solid tumors, including CRC	Maelig Morvan	Senti Biosciences, Inc
A-067	Next Generation Cytokine Immunotherapies for Solid Tumors.	Nicholas Huntington	oNKo-Innate Pty Ltd
A-068	High-throughput screening and single-cell transcriptomics identify synergies between oncology drugs and natural killer cell immunotherapy in hematological malignancies	Jonas Bouhlal	Hematology Research Unit Helsinki, University Of Helsinki And Helsinki University Hospital
A-069	Multi-OMICS profiling of a novel generation of trifunctional anti-CD123 Natural Killer Cell Engager in AML	Angela Virone-Oddos	Sanofi Immuno-Oncology Research
A-070	Acute myeloid leukemia patients trigger distinct activation patterns in expanded NK cells upon treatment	Hanna Duàn	Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital
A-071	Improving stem cell-derived natural killer cell immunotherapy against ovarian carcinoma with IL-15 transpresentation	Marcos Vidal Manrique	Laboratory of Hematology, Radboudumc
A-072	iPSC-derived NK cells expressing the high affinity IgG Fc receptor fusion CD64/16A for optimized ADCC and multi-tumor antigen targeting	Kate Dixon	University of Minnesota

POSTER	CONTENT	AUTHOR	REPRESENTING
A-073	Novel targeting of MICA/B enhances NK cell therapy against multiple myeloma	Aimee Merino	University of Minnesota
A-074	Engineered NK cells containing deleted TGF-βR2 and NR3C1 in recurrent glioblastoma	Mayra Shanley	Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center
A-075	NK-Derived Extracellular Vesicles (EVs) as a Treatment for Multiple Myeloma	Jacki Kornbluth	Saint Louis University
A-076	Siglec-7 down-modulation on hcmv-induced adaptive nk cells in healthy individuals and patients after hematopoietic stem-cell transplantation	Dana Vu Van	DKMS gGmbH, Clinical Trials Unit
A-077	Leveraging donor variability through large-scale production of NK cells from cord blood stem cells expanded with a novel small molecule	Stefanie Maurer	Immunebridge
A-078	Optimizing B7-H3-Specific Targeting of Metastatic, Castration-Resistant Prostate Cancer by Natural Killer Cells Using Patient Biopsy and Peripheral Blood Samples	Nicholas Zorko	University of Minnesota, Masonic Cancer Center
A-079	Allogeneic NK Cell Therapy for Lymphoma Revealed Cross-Talk with Adaptive T-Cell Immunity: Insights from Tumor Microenvironment Spatial Analysis	Veronika Bachanova	University Of Minnesota
A-080	Genetic Ablation of Adhesion Ligands Effectively Averts Rejection of Allogeneic Immune Cells	Quirin Hammer	Karolinska Institute
A-081	Deletion of the TMEM30A gene allows leukemic cell evasion of NK cell cytotoxicity	Linnea Kristenson	TIMM Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg
A-082	TGFβ-conditioned K-NK cells are able to counter immune suppression in the tumor microenvironment	Andre Kunert	Sanofi
A-083	Cellular therapy of cytokine induced memory-like NK cells for the treatment of head and neck cancer	Michal Sheffer	Dana Farber Cancer Institute
A-084	High-throughput evaluation of the potential of cancer drugs to enhance natural killer cell cytotoxicity in chronic myeloid leukemia	Petra Nygren	Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital
A-085	NK cell receptor-ligand expression patterns predict responsiveness against pancreatic cancer	Stacey Lee	Dalhousie University
A-086	Taking advantage of the complexity of Life: a new class of NK cell-based immunotherapy	Sabine Herblot	CHU Ste-Justine Research Center
A-087	CRISPR/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-directed CAR-NK cells	Tobias Bexte	University Hospital Frankfurt, Department for Pediatrics, Goethe University
A-088	HuR-dependent NK cell expansion mediate control of primary tumors without affecting clearance of tumor metastases.	Sytse Piersma	Washington University In St Louis
A-089	PD-L1 ligation enhances NK cell cytotoxicity by inducing metabolic shift	Katja Srpan	Memorial Sloan Kettering Cancer Center
A-090	EGFR/EGFRvIII-targeted CAR-NK cells as promising allogeneic cell therapy concept against solid tumors	Lisa Marie Reindl	University Hospital Frankfurt, Department of Pediatrics, Goethe University

POSTER	CONTENT	AUTHOR	REPRESENTING
A-091	Development of induced pluripotent stem cell-derived natural killer cells targeting breast cancer cells	Gustavo Rodrigues Rossi	Frazer Institute - The University Of Queensland
A-092	Bispecific Checkpoint Blockade Against KIR and NKG2A Receptors with Improved Functional Properties	Pilar Maria Lanuza	Karolinska Institutet
A-093	INTRO-study: Intraperitoneal infusion of allogeneic stem-cell derived natural killer cells in recurrent ovarian carcinoma patients	Paul de Jonge	Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center
A-094	Cytotoxic function of KIR2DS1+ NK cells in HLA-C2 homozygous DLBCL patients and healthy donors	Johanna Jansky	Biophysics, Center for Integrative Physiology and Molecular Medicine (CIPMM), School of Medicine, Saarland University
A-095	Dissecting the phenotype, plasticity and function of tumor-reactive NK cells in response to immunotherapy	Thuy Luu	University Hospital Basel
A-096	Engineered IL-2, SAR'245, enhances K-NK proliferation and cytotoxicity	Anna Oja	Sanofi Oncology Research
A-097	The potential of CAR-NK cells as targeted immunotherapy for head and neck squamous cell carcinoma	Sonya Ioana Ciulean	Fraunhofer Institute for Cell Therapy and Immunology (IZI)
A-098	The role of persistent AP-1 activation in NK cell exhaustion programming in AML	Erin Jeremy	Biomedical Sciences Graduate Program, Medical Scientist Training Program, The Ohio State University
A-099	Crosstalk between NK cells and myeloid blasts leads to an epigenetic state of exhaustion	May Daher	Md Anderson Cancer Center
A-100	In vitro pre-clinical study of NK cell response to ThINKK therapy in transplanted children with high-risk cancers	Emilie Ollame-Omvane	CHU Ste-Justine Research Center
A-101	SARS-CoV-2 evades NK-cell immunity by ORF6-mediated shedding of NKG2D ligands, uncovering a novel immunotherapeutic target conserved among sarbecoviruses	Wilfredo F. Garcia-Beltran	Ragon Institute of Mass General, MIT and Harvardarvard
A-102	Exportin-1 (XPO-1) as a target for natural killer cells in hepatocellular carcinoma	Salim Khakoo	University of Southampton
A-103	ADAPT-NK Immunotherapy: A Promising Approach for Treating Soft-Tissue Sarcomas and Overcoming Immune Cold Tumor Microenvironments	Marianna Vincenti	Institute for Cancer Research - Oslo University Hospital
A-104	Characterization of human tissue-resident NK cells in the hepatocellular carcinoma microenvironment	Jules Russick	Karolinska Institutet - CIM
A-105	Targeting HLA-E Positive Cancers with a Novel A/C Switch Receptor	Michelle Sætersmoen	Institute of Clinical Medicine, University of Oslo
A-106	Development of CD276 CAR-NK cells for a potential therapy of solid tumor	Pulak Nath	Miltenyi Biotec
A-107	NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of HER2-targeted antibodies in HER2 positive breast cancer.	Aura Muntasell	Hospital del Mar Medical Research Institute
A-108	CD70-expressing tumor cells and cancer-associated fibroblasts of the tumor microenvironment are effectively eliminated by IL-15-armored CD70-directed CAR natural killer cells	Astrid Van den Eynde	Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp

POSTER	CONTENT	AUTHOR	REPRESENTING
A-109	Mass Cytometry and Functional Analysis of NK cells on CTN-1101 Trial to Determine the Impact of Graft Source on Immune Reconstitution	Peter Hinderlie	University of Minnesota
A-110	Transcriptomic evaluation of NK lymphocytes from ovarian cancer-associated ascites.	Fernando Guimarães	Women's Hospital - Campinas University - Unicamp
A-111	The STK38(L) signalling pathway in NK cells: a promising novel target for cancer immunotherapy	Faith O. David	St. Anna Children's Cancer Research Institute GmbH
A-112	An HIV Envelope tri-specific killer engager (TriKE) directs NK killing against envelope expressing cells and synergizes with the HDAC inhibitor, SAHA to reactivate latently infected cells	Zach Davis	University Of Minnesota
A-113	Co-mutations with KRAS associate with NK cell mediated control of non-small cell lung carcinoma.	Leah MacLean	Department of Pathology, Dalhousie University
A-114	Galectin-3 – an immune modulator in ovarian cancer	Veronika Karlsson	Department of Oral Microbiology and Immunology, Institute of Odontology, Sahlgrenska Academy at the University of Gothenburg
A-115	Engineering Natural Killer (NK) Cells to Target HIV Reservoirs in Secondary Lymphoid Organs	Ruoxi Pi	Department of Medicine, Division of Infectious Diseases, Stanford University School of Medicine
A-116	Preclinical development of affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells	Thorstein Boxaspen	Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital
A-117	Heterogeneity of CD49a+CD103+ Tissue-Resident NK Cells in Solid Tumors	John Sunwoo	Stanford University
A-118	Elucidating molecular mechanisms of NK cell desensitization and exhaustion	Yeara Jo	University Of California, Berkeley
A-119	Anti-CD33 CAR NK cells eliminate NK-resistant AML targets more effectively with co-stimulation via 4-1BB compared to CD28, independent of other structural elements.	Kyle Beckwith	Ohio State University
A-120	Engineering NK cells for Enhanced Persistence and Cytotoxic Function to Improve their Cancer Immunotherapy Potential	Caroline Eriksson	Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet
A-121	Combining electroporation and lentiviral transduction for the generation of highly potent primary CAR NK cells for cancer immunotherapy	Congcong Zhang	Miltenyi Biotec B.V. & Co. KG, R&D Reagents
A-122	Promising immunoconjugates activating NK cells for PDAC treatment	Camille Rolin	Department of Infection and Immunity, Luxembourg Institute Of Health
A-123	Generation of universal cellular grafts utilizing signaling-deficient membrane-bound CD45 engagers	Alamdar Hussain	Division of Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet,
A-124	CDK4/6 inhibitor palbociclib selectively inhibits proliferation and survival of immature human NK cell subsets	Yong-Oon Ahn	Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center
A-125	A clinical-grade manufacturing process using CliniMACS Prodigy® for CAR-NK cell-based immunotherapy	Dominika Lukas	Miltenyi Biotec B.V. & Co. KG
A-126	Enhancing the anti-tumor activity of natural killer cells through optimization of next- generation chimeric antigen receptors	Marcella Cardoso	Ragon Institute of MGH, MIT and Harvard

POSTER	CONTENT	AUTHOR	REPRESENTING
A-127	Plasma Membrane Embedded System for Spatiotemporal Controlled Payload Delivery by Natural Killer cells	Dara Mohammad	Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet
A-128	The anti-EGFR cetuximab synergizes with blocking of the immune checkpoint ligand PVR to provoke a natural killer cell response against head and neck squamous cell carcinoma.	Jorrit De Waele	Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp
A-129	Unveiling the Diversity of NK Cell Populations in High-Grade Serous Ovarian Cancer: Associations between scRNAseq-Defined NK Cell Cluster Frequencies and Ligand Expression	Sarah Nersesian	Department of Microbiology and Immunology, Dalhousie University
A-130	The spike protein of SARS-CoV-2 modulates NK cell responses via enhanced HLA-E expression	Lutz Walter	Primate Genetics Laboratory, German Primate Center, Leibnitz-Institute for Primate Research
B-001	CD11d, an NK cell ally in their fight against tumours	Capucine Bourel	Hôpital Maisonneuve-Rosemont
B-002	Ontogeny and functionality of murine brain innate lymphoid cells.	Alba Del Rio Serrato	Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine (MDC)
B-003	Identification and function of a novel human memory-like NK cell population expressing CD160 in melioidosis	Anucha Preechanukul	Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University
B-004	Comparison of the different anti-CD16 antibody clones in the activation and expansion of peripheral blood NK cells	Jeehun Park	Seoul National University
B-005	Role of the inhibitory receptor CD200R in ILC1 development and function	Yawen Chen	Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, Biomedical Sciences and Health Laboratory of Anhui Province, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China
B-006	Tissue-resident but not conventional NK cells access tissue parenchyma and recirculate via lymphatics at steady state	Annika Niehrs	Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet
B-007	Liver sinusoidal endothelial cells orchestrate NK cell recruitment and activation in acute inflammatory liver injury	Sophia Papaioannou	Department of Immunobiochemistry, Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Heidelberg University
B-008	NK cell senescence as barrier to malignant transformation	Dagmar Gotthardt	University of Veterinary Medicine Vienna, Department of Biomedical Sciences
B-009	Reciprocal interactions between uterine NK cells and extravillous trophoblast promote successful placentation in humans.	Ashley Moffett	University of Cambridge, Department of Pathology
B-010	Regulation of NK cell responses by macrophage-derived 25-hydroxycholesterol	Cathal Keane	School of Biochemistry and Immunology
B-011	Importance of the amino acid transporters Slc1a5 and Slc7a5 for sustaining NK cell function	Carrie Corkish	Trinity Biomedical Sciences Institute, Trinity College Dublin
B-012	Determining natural killer cell responses to JC polyomavirus	C. Sabrina Tan	University Of Iowa
B-013	An optimized platform for efficient siRNA delivery into human NK cells	Pouria Momayyezi	Karolinska Institutet, Department of Medicine Huddinge
B-014	Identifying a minimal combination of transcription factors to induce the direct differentiation of human pluripotent stem cells to natural killer cells	Claire Marsal	Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet, SE-141 83

POSTER	CONTENT	AUTHOR	REPRESENTING
B-015	Dichotomous roles of TNFR1 and 2 signaling in NK cell-mediated immune responses during inflammation	Timothy McCulloch	Frazer Institute, University of Queensland
B-016	Comparative assessment and identification of optimal promoters for genetic modification of NK cells throughout differentiation stages from pluripotent sources	Hazel Reilly	Karolinska Institutet
B-017	Mature NK cells are targeted by Staphylococcus aureus leukocidin ED	Caroline Boulouis	Center for Infectious Medicine, Department of Medicine, Karolinska Institutet
B-018	Genome-wide CRISPR-Cas9 screen for the elucidation of novel mediators of cytotoxicity in natural killer cells	Nutsa Burduli	Center for Hematology and Regenerative Medicine (HERM), Karolinska Institutet
B-019	Tracking tissue-dependent gene expression in fetal NK cells at the clonal level	Inga Elisabeth Rødahl	Center for Infectious Medicine, Dep. of Medicine, Karolinska Institute
B-020	Characterisation of organ-specific tissue-resident NK cells across human tissues	Nicole Wild	Center for Hematology and Regenerative Medicine, Department of Medicine
B-021	INK4a/ARF is upregulated in senescent NK cells and acts as a barrier to leukemic transformation	Julia List	Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna
B-022	Revealing unknown evasion mechanisms of leukemic cells from natural killer cells	Michelle C. Buri	St. Anna Children's Cancer Research Institute
B-023	Prostaglandin E_2 impacts multiple stages of the NK cell anti-tumour immune response from migration to killing	Chloe Patterson	The Lydia Becker Institute of Immunology and Inflammation, The University of Manchester
B-024	NK cells regulate CD8+ T cell homeostasis in the murine submandibular glands	Samantha Borys	Brown University
B-025	TCF19 control of NK cell immunity	Celeste Dang	Memorial Sloan Kettering
B-026	Loss of Siglec-7 correlates with enhanced NK cell function and protection from malaria	Jenna Dick	Department of Medicine, Division of Infectious Diseases and International Medicine, University of Minnesota
B-027	Distinct requirements among members of the ly49 receptors in mediating adaptive nk cell responses	Gayani Gamage	Dalhousie University
B-028	Characterization of the chromatin and transcriptional landscapes of intratumoral NK cells using single cell multiomics	Clara Serger	Department of Biomedicine, University Hospital Basel
B-029	Defining the tissue signature of natural killer cells in the female reproductive tract	Sarah Vick	Fred Hutchinson Cancer Center
B-030	Control of nutrient uptake by IRF4 orchestrates innate immune memory	Endi Santosa	Weill Cornell Medicine / Memorial Sloan Kettering
B-031	Selective expression of the activating receptor NKp65 demarcates human ILC3 from mature NK cells	Ines Kühnel	Institute for Molecular Medicine, Goethe University
B-032	Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B	Frederik Feigl	Fraunhofer Institute for Cell Therapy and Immunology (IZI)

POSTER	CONTENT	AUTHOR	REPRESENTING
B-033	T regulatory cells suppress NK and CD4 T cell responses against MHC I-deficient tumors	Chenyu Zhang	University Of California, Berkeley
B-034	Regulation of NK Cell Effector Function by Acetylation	Stacey Sohn	Department of Pediatrics, Division of Rheumatology & Immunology, Washington University School Of Medicine
B-035	IFNg- and sialic acid pathways drive melanoma resistance via selective inhibition of NK cell subsets.	Tomas Hofman	Mannheim Institute for Innate Immunoscience (MI3), Department of Immunobiochemistry, Heidelberg University, Medical Faculty Mannheim
B-036	Transcription factor RORα promotes the formation and long-term maintenance of memory ILC1s	Ming Cheng	Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei
B-037	Comparison of ILC progenitor heterogeneity in the adult bone marrow and fetal liver	Jiarui Li	Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China
B-038	Unveiling the Mechanisms of NK Cell Defense Against Fungal Infections: Exploring the Crucial Role of Conserved Surface Proteins in the NK Cell-Fungus Interaction	Fariha Natasha	Department of Biotechnology and Biophysics,University of Wuerzburg
B-039	NK cell defects occur at the pre-MDS blast-free stage in NHD13 mouse model	Ewa Sitnicka	Division of Molecular Hematology, Lund Stem Cell Center, Lund University
B-040	Tumour-priming induces memory-like properties on NK cells: characterisation of the proteomic and receptor profile	Helena Arellano Ballestero	University College London
B-041	Functional consequences of the use of homodimeric or heterodimeric states of the adaptor proteins CD3ζ and FcεR1γ in the CD16-induced activation of human and mouse NK cells	Indrani Nayak	Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute, Nationwide Children's Hospital
B-042	Modulation of effector functions of NK cells by human plasma derived IgG and recombinant IgG Fc fragment	Daniela Reis Galvao	Division of Immunology and Allergology, Department of Medicine,Faculty of Medicine, University Hospitals Geneva
B-043	NK humanized mouse models for the in vivo evaluation of anti-tumor NK-cell therapies	Pauline Rettman	Sanofi R&D Oncology Research, Pharmacology
B-044	Differentiation of induced-pluripotent stem cell-derived NK cells in physiological (5%) oxygen leads to enhanced persistence and tumor control in an animal model of AML	Philippa Kennedy	University Of Minnesota
B-045	Development and function of liver-resident NK cells/ ILC1s: from fetal to adult life	Hui Peng	Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China
B-046	Uncoupling of Natural Killer cell functional maturation and cytolytic function in NOD mice	Felix Lombard-Vadnais	Maisonneuve-rosemont Hosptial
B-047	Nano-engineering of Chem_NK to be resistant to TGFβ	Kyung-Soon Park	CHA University
B-048	Activating KIR are not weak but peptide specific	Malcolm Sim	NIAID, NIH
B-049	Exhaustion induces transcriptional and epigenetic alterations in human NK cells that weaken NK cell activation through reduced ERK1/2 signaling and cell migration	Jake Myers	University Of Minnesota
B-050	TGF-β1 induces CD34+ progenitor-derived NK-cell dysfunction associated with ovarian cancer	Iris Hagemans	Department of Laboratory Medicine, Radboudumc

POSTER	CONTENT	AUTHOR	REPRESENTING
B-051	Optimizing adoptive transfer of mouse NK cells to facilitate immunoregulatory research	Laura Canaday	Immunology Graduate Training Program, University of Cincinnati College of Medicine
B-052	TGF-β converts mature NK cells into tissue residency-like cells through SMAD3 independent pathways.	Ezgi Elmas	The Ohio State University
B-053	Lysis of P. falciparum-infected erythrocytes by NK cells requires ligand-specific recognition and releases parasitophorous vacuoles that are phagocytosed by monocytes in the presence of immune IgG	Sumi Rajagopalan	Molecular and Cellular Immunology Section, Laboratory of Immunogenetics, NIAID/NIH
B-054	Functional genomics identifies N-acetyl-lactosamine extension of branched N-glycans as a mechanism to evade lysis by NK cells	Eric Long	Laboratory of Immunogenetics, NIAID-NIH
B-055	IL-12/15/18 induces the formation of two subsets of cytokine-induced memory-like NK cells that are phenotypically, transcriptionally, epigenetically, and functionally distinct	Jennifer Foltz	Washington University School Of Medicine
B-056	Education of uterine natural killer cells results in transcriptomic reprogramming	Delphine Depierreux	Division of Human Biology, Fred Hutchinson Cancer Center
B-057	Leveraging MINFLUX Nanoscopy to Understand NK Cell Immunological Synapse Structure and Dynamics	Patrick Ross	San Diego Biomedical Research Institute
B-058	PP2A negatively regulates NK cell T-bet expression and effector function	Yui Yamamae	University of Toyama
B-059	Regulatory functions of vitamin A-treated natural killer cells	Ana Stojanovic	Department of Immunobiochemistry, MI3, Heidelberg University
B-060	Fine-tuning of NK cell responses by the HIF-1α–AhR pathway	Francesco Cortopassi	Department of Immunobiochemistry, Mannheim institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Heidelberg University
B-061	The methyltransferase DOT1L controls NK cell activation and lineage integrity.	Sebastian Scheer	Monash University
B-062	Human Natural Killer cells which lack CD70 are strongly cytolytic while those expressing CD8a are adept at serial killing	Katherine Louise Jones	University of Manchester
B-063	Investigating clonality in NKG2C- adaptive natural killer cells	Maximilian Mandry	Innate Immunity, Deutsches Rheuma-Forschungszentrum
B-064	A Temporal Transcriptional Reference Map of Human Natural Killer Cells	Herman Netskar	Institute of Clinical Medicine, University of Oslo
B-065	Zebrafish as a novel in vivo model to assess CAR-NK cell efficacy against metastatic breast cancer	Nivedha Murali Shankar	Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology
B-066	Dissecting the innate lymphoid cell landscape of the human biliary tract system	Daniel Geanon	Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital
B-067	In situ clonal tracing of group 1 ILCs across mouse peripheral tissues	Emma Patey	Center for Infectious Medicine, Karolinska Institutet
B-068	Adaptive NK cells responses against antigenically distinct influenza viruses are partly mediated by HLA-E-stabilizing peptides derived from conserved antigens	Stephanie Jost	Division of Innate and Comparative Immunology, Center for Human Systems Immunology, Department of Surgery, Duke University School of Medicine

POSTER	CONTENT	AUTHOR	REPRESENTING
B-069	Heterotypic tumor spheroid models for cellular immunotherapy	Valentina Carannante	KTH Royal Institute of Technology
B-070	Tumor-infiltrating NK cells have distinct metabolic features on diverse tumor models	Cristhiane Favero De Aguiar	Trinity College Dublin
B-071	Human cytomegalovirus genes UL148 and UL148D inhibit NK cell function by promoting surface expression of inhibitory ligands via impairment of ADAM17	Anzelika Rubina	Cardiff University, School of Medicine, Division of Infection and Immunity, Henry Wellcome Building, Heath Park
B-072	Cytokine-induced memory-like natural killer cell differentiation is interrupted by mitochondrial damage-associated molecular patterns (mitoDAMPs)	Lauren Westhaver	Department of Pathology, Dalhousie University
B-073	Effect of maternal HIV exposure on infant NK cell transcriptional profiles over the first year of life	Cheryl Day	Emory University
B-074	Chromosomal rearrangements in the KIR gene cluster as evolutionary strategy to fight fast evolving pathogens	Jesse Bruijnesteijn	Bprc
B-075	Deciphering human NK cell development using high-dimensional phenotyping and imaging: tonsil versus thymus	Janine Melsen	Laboratory for Pediatric Immunology, Willem-Alexander Children's Hospital, Leiden University Medical Center
B-076	Investigation of the expression and function of CD96 (TACTILE) on human uterine NK cells	Corinna Mayer	Medicine, Huddinge, Karolinska Institutet
B-077	Inhibition of the regulatory checkpoint ADAM17 enhances NK cell proliferation by IL-15 through increased CD137 co-stimulation	Bruce Walcheck	University of Minnesota
B-078	Peculiarities of porcine innate immune cells revealed by natural cytotoxicity receptors NKp46 and NKp44	Kerstin Mair	Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna
B-079	A multifaceted deep dive into the NK cell developmental niche within human secondary lymphoid tissue.	Everardo Hegewisch-Solloa	Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center
B-080	Ligand mobility is necessary for TIGIT to assemble into nanoscale clusters at immune synapses	Roseanna Kate Hare	University Of Manchester
B-081	Targeting and activation of NK cells using cytokine-functionalized immunofilaments	Lea Weiss	Radboud University Medical Center
B-082	Early antigen-receptor signaling primes NK cells for optimal cytokine signaling during infection	Simon Grassmann	Memorial Sloan Kettering Cancer Center
B-083	The role of CD200R1 in NK-cell development and function	Youssef Youssef	The Ohio State UniversityCollege of Medicine, The Ohio State University Comprehensive Cancer Center
B-084	Protecting mitochondrial health prevents hypoxia-induced natural killer cell dysfunction	Tias Verhezen	Center for Oncological Research (CORE), Integrated Precision and Personalized Oncology Network (IPPON), University of Antwerp
B-085	KINESIN-1 IS REQUIRED FOR NK CELL GRANULE-MEDIATED FUNGAL CYTOTOXICITY TO CRYPTOCOCCUS NEOFORMANS	Adley CH Mok	Cumming School of Medicine, University Of Calgary
B-086	SHP-1 Function and Regulation in Natural Killer Cell Education	Sophia Hald	HERM, Department of Medicine, Huddinge

POSTER	CONTENT	AUTHOR	REPRESENTING
B-087	Identification of serial killing human NK cells	Jens Niemann	Leibniz Research Centre For Working Environment And Human Factors
B-088	Deciphering vitamin A- and D-mediated regulation of human NK cells for cellular immunotherapy	Sigrid Wahlen	Department of Medicine, Karolinska Institutet
B-089	Essential role of Ugcg for natural killer cell homeostasis and cytolytic function	Tasha Morrison	NIAMS/NIH
B-090	Tissue-specific determinants of adaptive NK cell responses	Adriana Mujal	1Immunology Program, Memorial Sloan Kettering Cancer Center
B-091	High Natural Killer Cell Proportion and Immune Activation Correlate with Low Neutralization Breadth in Wild Type SARS-CoV-2 Infection	Izumi de los Rios Kobara	Immunology Program, Stanford University
B-092	HIV-1 infection of macrophages primes CD56dim NK cells to produce antiviral cytokines	Leonore Mensching	Leibniz Institute of Virology (LIV)
B-093	Detailed phenotypic and functional characterization of CMV-associated adaptive NK cells in rhesus macaques	Lutz Walter	German Primate Center
B-094	The Lysosomal Calcium Channel TRPML1 Maintains Mitochondrial Fitness in Natural Killer Cells through Inter-organelle Cross Talk.	Edina Szabo	Department of Cancer Immunology, Institute of Cancer Research, Oslo University Hospital
B-095	HLA-E protects genetically engineered porcine endothelial cells from lysis by natural killer cells in 2D and 3D microfluidic systems	Thao Tran	Laboratory of Translational Immunology, Department of Medicine, University Hospitals and Faculty of Medicine
B-096	Clonally heritable gene and protein expression in human NK cells	Jakob Michaelsson	Dep of Medicine Huddinge, Karolinska Institutet
B-097	Effects of Blocking the Metalloprotease ADAM17 on the Generation of Cytokine Induced Memory-Like NK Cells	Robert Hullsiek	University Of Minnesota
B-098	Establishing Tonsil and Splenic Organoids as a Model of HIV-Infection to Evaluate Engineered NK Cells' Killing of HIV-Infected Cells	Sarah Sackey	Immunology Program, Stanford University
B-099	Lineage-determining transcription factors use sense/antisense promoter competition to program cell fate	Stephen Anderson	Basic Research Program, Frederick National Laboratory for Cancer Research
B-100	NK cell lysis of activated T cells via the KIR3DS1:HLA-F axis in the context of HIV-1 infection.	Timo Trenkner	Leibniz Institute For Virology
B-101	Unveiling the roles of unconventional subsets and other Innate Lymphoid Cells in human Natural Killer cell ontogenesis: the development of an autologous Bone Marrow niche mimicking system	Alessandro Frigo	Department of Medical Biotechnology and Translational Medicine, University of Milan
B-102	Mapping human tissue-resident NK cells across adult intestinal tissues	Nicole Marquardt	Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet
B-103	Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells.	Paul Norman	University Of Colorado
B-104	Nurture shapes natural killers through epigenetic regulators	Xi Wang	Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases,Beijing Ditan Hospital, Capital Medical University

POSTER	CONTENT	AUTHOR	REPRESENTING
B-105	Exploring the complexities of AHR gene regulation in cell differentiation	Hongchuan Li	Basic Science Program, Frederick National Laboratory for Cancer Research
B-106	Intraluminal vesicles within cytolytic granules are dependent on NKG7 and contribute to apoptosis of target cells	Yunjie Wu	Department of Pharmacology, Institute of Clinical Medicine, University of Oslo
B-107	The costimulatory domains of CD5-directed CAR NK cells determine their fate	Rafet Basar	UT MD Anderson Cancer Center
B-108	BAP1 deletion disrupts IFNγ signaling and sensitizes cancer cells to NK cell cytotoxicity	Chiara Badami	TIMM Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg
B-109	Neutrophil serine proteases process IL-18 to a cytokine variant with enhanced activity	Anne Wöhr	Sahlgrenska Center for Cancer Research, University of Gothenburg
B-110	A novel human NK cell progenitor that originates in the thymus and generates NKG2A-KIR+ NK cells	Markus Uhrberg	Institute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, Heinrich-Heine University Düsseldorf
B-111	NKG2A blockade overcomes adaptive resistance to anti-HER2 antibodies in HER2-positive breast cancer, impact of genetic factors and antibody-drug conjugates.	Aura Muntasell	Hospital del Mar Medical Research Institute
B-112	An inflammation-induced transcriptomic program governing functional capacity of human NK cells	Harrison "Alex" Feldman	Center for Autoimmune Genomics and Etiology, Division of Human Genetics, Cincinnati Children's Hospital Medical Center
B-113	DEF6 promotes canonical CD56dim NK cell survival and cytotoxicity	Giovanna Perinetti Casoni	Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute
B-114	Clonal tracing and transcription factor network analysis refined the identities of developmental intermediate stages between human nk cells and non-cytotoxic ilc subsets via a comprehensive in vitro model	Dang Nghiem Vo	Lund Stem Cell Center
B-115	Genome Organizer SATB1 Regulates NK Cell Effector Function and Apoptosis during MCMV Infection	Mark Owyong	Immunology and Microbial Pathogenesis Program, Weill Cornell Medicine
B-116	Fatty acid metabolism promotes natural killer cell cytotoxicity and anti-tumor function	Sam Sheppard	Imperial College London
B-117	Serial-killing NK cells maintain high signaling over successive interactions	Björn Önfelt	KTH Royal Institute of Technology
B-118	Direct reprogramming Informs on Transcription Network Initiating Natural Killer Program	Inês Caiado	Molecular Medicine and Gene Therapy, Lund Stem Cell Center
B-119	MEF2C is a critical regulator of human NK cell metabolism	Joey Li	Department of Microbiology, Immunology, and Molecular Genetics, University Of California, Los Angeles
B-120	NKG2D facilitates the initial step of Citrobacter rodentium colonization of the intestinal epithelium	Renata Oliveira de Vasconcelos	Imperial College
B-121	Human adaptive FcεRIγ-/low NK cell signaling uncovered a link to diminished cell proliferation.	Avishai Shemesh	Department of Medicine, University of California, San Francisco, CA
B-122	Screening of the effect of animal venom on Natural Killer cells in the context of cancer	Amanda Pires Bonfanti	Department of Structural and Functional Biology, Institute of Biology UNICAMP

POSTER	CONTENT	AUTHOR	REPRESENTING
B-123	A novel platform enabling versatile genetic engineering in murine NK cells	Hsuan-An Chen	Memorial Sloan Kettering Cancer Center
B-124	Antibody bivalency and allostery promotes superior NK Cell ADCC activity	Daniel Murin	San Diego Biomedical Research Institute
B-125	Unveiling the pathway of IL-2 secretion in mbIL-21 expanded NK cells	Joseph R. Caporale	The Ohio State University
B-126	Genetic polymorphism predicts NKG2A expression and impacts lymphocyte phenotype and function	Jean-Benoît Le Luduec	Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
B-127	NKG2D enhances the dynamic interactions between NK cells and tumor cells	Oyku Ozcan	Imperial College London
B-128	CHARACTERIZATION OF TGF-BETA IMPRINTED CANINE NK CELLS	Samantha Sommer	Department of Veterinary Biosciences, The Ohio State University College of Veterinary Medicine
B-129	Genome-wide analysis of transcriptional and epigenetic effects of TGFβ-signalling on NK cells	Kevin Schmid	Department of Internal Medicine II, Technical University of Munich
B-130	Essential role of innate tissue lymphocyte production of interferon-gamma during viral infection	Rachael Philips	Lymphocyte Cell Biology Section, Molecular Immunology and Inflammation Branch (MIIB), National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS)
B-131	PD-L1 CAR K-NK cells for treatment of PD-L1+ and PD-L1- NSCLC	Andre Kunert	Sanofi

PARTICIPANTS

PARTICIPANT	POSTER
Adesina, Sherry*	
Acharya, Sunil	A-011, A-018, A-074, A-099, B-107
Aguilar, Oscar A.	B-041
Ahn, Yong-Oon	A-124
Alici, Evren	A-007, A-012, A-123, A-127, B-014, B-016, B-018
Alrubayyi, Aljawharah	A-063
Altfeld, Marcus	A-015, B-092, B-100
Amarilla-Irusta, Ainhoa	A-045, A-046
Anderson, Stephen	B-099, B-105
André, Pascal	
Aragam, Nina	
Arellano Ballestero, Helena	B-040
Astarloa-Pando, Gabirel	A-045, A-046
Bachanova, Veronika	A-079
Badami, Chiara	A-081, B-108
Barnes, Samantha	A-021
Barth, Kerstin	
Basar, Rafet	A-011, A-018, A-074, A-099, B-107
Bashirova, Arman	A-064
Beckwith, Kyle	A-119
Beiersdorfer, Maya	
Belïen, Jarne	B-092, B-100
Bernson, Elin	A-114
Berrien-Elliott, Melissa	B-055
Bexte, Tobias	A-087
Björklund, Andreas*	
Björkström, Niklas	A-054, A-104, B-006, B-066, B-067, B-076
Bjørnsen, Elisabeth	
Blanas, Athanasios	
Blish, Catherine	A-039, A-041, A-115, B-091, B-098
Borate, Sophia	A-007, B-014, B-016
Borrego, Francisco	A-045, A-046

PARTICIPANT	POSTER
Blish, Catherine	A-039, A-041, A-115, B-091, B-098
Bontrop, Ronald	B-074
Borate, Sophia	A-007, B-014, B-016
Borrego, Francisco	A-045, A-046
Borys, Samantha	B-024
Boudreau, Jeanette E.	A-085, A-113, A-129, B-072
Bouhlal, Jonas	A-059, A-068, A-070, A-084
Boulouis, Caroline	B-017
Bourel, Capucine	B-001, B-046
Boxaspen, Thorstein	A-116
Brossay, Laurent	B-024
Brownlie, Demi	A-012, B-020, B-102
Bruijnesteijn, Jesse	B-074
Bryceson, Yenan	A-120, B-088, B-113
Burduli, Nutsa	A-007, A-127, B-014, B-016, B-018
Buri, Michelle C.	A-111, B-022
Böhmer, Maren	
Caiado, Inês	B-118
Calder, Douglas	
Caligiuri, Michael	
Campbell, Amanda	
Campbell, Kerry	
Campbell, Tessa Mollie	B-113
Canaday, Laura	B-051
Caporale, Joseph R.	A-119, B-125
Cappel, Claudia	A-027
Carannante, Valentina	B-069, B-117
Carlsten, Mattias	A-013, A-120
Carrington, Mary	A-015, A-064, A-101
Cerwenka, Adelheid	B-007, B-035, B-059, B-060
Chabot-Roy, Geneviève	B-001, B-046
Chan, Carmel	A-042
Chan, Leslie	A-041
Chang, Chan-Jung	
Chen, Hsuan-An	B-123
Chen, Yawen	B-005, B-036, B-045

PARTICIPANT	POSTER
Cheng, Ming	B-036
Cheung, Wendy	
Cho, Hyunsoo	A-040
Choi, Seunghee	A-043, B-047
Christensen, Emil	
Cichocki, Frank	A-052, A-079
Ciulean, Sonya Ioana	A-097
Colonna, Marco	
Colucci, Francesco	B-056
Cooley, Sarah	
Cooper, Megan A.	B-034
Corkish, Carrie	B-011
Correia, Margareta	B-060
Corthay, Alexandre B.	
Cortopassi, Francesco	B-059, B-060
Cotari, Jesse	A-077
Crespo, Angela	
Curley, Michael	
Daher, May	A-011, A-018, A-074, A-099, B-107
Dahlberg, Carin	
D'Alessandri, Tim	A-051
Dang, Celeste	B-025
Das, Jayajit	B-041
Dash, Pradyot	A-106
David, Faith O.	A-111, B-022
Davis, Daniel M.	B-023, B-062, B-080, B-116
Davis, Zachary	A-062, A-072, A-073, A-109, A-112
Daws, Michael	
Day, Cheryl	B-073
de Jonge, Paul	A-057, A-061, A-071, B-081, A-093, B-050,
de Lima, Jean	A-032
de los Rios Kobara, Izumi	B-091
De Waele, Jorrit	A-047, A-108, A-128, B-084
Degli-Esposti, Mariapia	B-061
Del Rio Serrato, Alba	B-002
Delconte, Rebecca	A-031

PARTICIPANT	POSTER
Delso Vallejo, Maria	
Depierreux, Delphine	B-056
Devaux, Carole	A-122
Diao, Yumei	A-116
Dick, Jenna	B-026
Diefenbach, Andreas	B-002
Dissen, Erik	
Dixon, Kate	A-072, B-077, B-097
Dolstra, Harry	A-057, A-061, A-071, A-093, B-050, B-081
Donati, Daria*	
Duàn, Hanna	A-059, A-070
Dufva, Olli	A-059, A-068, A-070, A-084
Dunbar, Cynthia	
Duval, Michel	A-086, A-100
Eitler, Jiri	A-016, A-020, B-065
Elmas, Ezgi	B-052, B-128
Eriksson, Caroline	A-120
Fardellas, Achilleas	
Farley, William	
Favero De Aguiar, Cristhiane	B-070
Fehniger, Todd	B-055
Feigl, Frederik	B-032
Feldman, Harrison A.	B-051, B-112
Felices, Martin	A-052, A-053, A-062, A-065, A-078, A-079, A-109, A-112, B-044, B-049, B-077
Fernandes, Aristi	
Finizio, Rob	
Foltz, Jennifer	B-055, B-128
Franzese, Sara	A-034
French, Anthony	
Freud, Aharon	A-098, A-004, B-079, B-083, B-099, B-105
Frigo, Alessandro	B-101
Galan Diez, Marta	
Gamage, Gayani	B-027

PARTICIPANT	POSTER
Garcia-Beltran, Wilfredo	A-064, A-101, A-126, B-092, B-100
Gardiner, Clair	A-025
Geanon, Daniel	B-066
Gehrcken, Laura	A-047, A-108, B-084
Gelius, Stefan Svensson	
Germeraad, Wilfred	
Ghaderi, Amineh	A-060
Gimeno Arias, Lourdes	A-037, A-038
Gotthardt, Dagmar	B-008, B-021
Graf-Pfeuffer, Viktoria	
Grassmann, Simon	B-082, B-090
Grotens, Ayla	A-057
Guerra, Nadia	B-120, B-127
Guia Da Silva, Sophie	A-026
Guimarães, Fernando	A-110, B-122
Hagemans, Iris	B-050
Hald, Sophia	B-086
Hammer, Quirin	A-080, A-092, A-123, A-105, B-013
Hare, Roseanna Kate	B-080
Hayakawa, Yoshihiro	B-058
Hayal, Taha	
Hegewisch-Solloa, Everardo	B-075, B-079
Heidenreich, Falk	A-076
Hengst, Julia	A-058, B-006
Herblot, Sabine	A-086, A-100
Hereng, Tuva H.	
Hinderlie, Peter	A-062, A-065, A-078, A-109, B-044, B-049
Hoel, Hanna Julie	A-103
Hölzemer, Angelique	A-015, A-101, B-092, B-100
Hofman, Tomas	B-035
Holm, Anders*	
Holmqvist, Per-Henrik	
Hooijmaijers, Laura	A-061, A-071, B-050
Horowitz, Amir	A-103, B-079
Horowitz, Nina	A-077, A-117

PARTICIPANT	POSTER
Hsu, Katharine C.	A-031, A-089, B-030, B-116, B-126
Hullsiek, Robert	A-072, B-077, B-097
Huntington, Nicholas	A-067, B-061
Hussain, Alamdar	A-007, A-123, A-127, B-014, B-016
Höglund, Petter	B-086
Igarashi, Robert	A-082, B-131, A-096
Inngjerdingen, Marit	B-106
Isles, Hannah M.	
Ivarsson, Martin	B-006, B-019, B-076
Iyer, Sumanth	
Jang, Yong-Suk	
Jansky, Johanna	A-094
Jeremy, Erin	A-098, B-083
Jo, Yeara	A-118
Jones, Katherine Louise	B-062
Jost, Stephanie	B-012, B-068
Jørgensen, Lasse V.	
Karlsson, Veronika	A-114
Kaufman, Dan	
Kaufman, Gunnar*	
Keane, Cathal	B-010
Kee, Barbara	
Kennedy, Philippa	A-053, A-062, A-065, B-044
Khakoo, Salim	A-102
Khaw, Melissa	A-062, A-065, A-072, A-078, B-077
Kiesewetter, Anne	
Kim, Yeonhee	A-040
Kistenmacher, Ann-Kathrin	A-050
Knight, Oliver	A-008
Koh, Seung Kwon	
Kornbluth, Jacki	A-075
Kotchetkov, Ivan*	A-105
Kristenson, Linnea	A-081, B-108
Krämer, Benjamin	B-083
Kumar, Akhilesh	
Kunert, Andre	A-082, B-131, A-096

PARTICIPANT	POSTER
Kveberg, Lise	
Kwak, Jeong-Eun	A-040
Köhl, Ulrike	A-027, A-050, A-097
Kübler, Ayline	A-056
Kühnel, Ines	A-022, A-048, B-031
Lan, Yi Jun	A-010
Landsverk, Ole	
Lanier, Lewis L.	B-041, B-121
Lanuza, Pilar Maria	A-092
Laugel, Bruno	A-014
Le Luduec, Jean-Benoît	B-030, B-126
LeSavage, Bauer	A-077
Lee, Dean A.	A-055, A-059, A-068, A-070, A-084, A-119, A-005, A-044, B-052, B-128, B-125
Lee, Madeline	A-039, B-091
Lee, Seung-Hwan	A-036
Lee, Stacey N.	A-085; A-129, B-072
Leito, Jelani	
Lesage, Sylvie	B-001, B-046
Li, Hongchuan	B-099, B-105
Li, James (Tianjian)	
Li, Jiarui	B-036, B-037
Li, Joey	B-119
Liao, Yi-chu	
Lim, Yuree	
Linkenbach, Sophie-Christin	A-056
List, Julia	B-008, B-021
Liu, Dongfang	A-009
Liu, Qiang	
Ljunggren, Hans Gustaf	A-012, A-123, B-018
Lombard-Vadnais, Felix	B-001, B-046
Long, Eric	B-048, B-053, B-054
Loreti, Mafalda	
Lozada, John Roy	A-052, A-078
Lukas, Dominika	A-125
Luu, Thuy	A-095, B-086

PARTICIPANT	POSTER
Ma, Minh	
MacLean, Leah	A-113
Mace, Emily M.	B-075, B-079, A-124
Maguire, Colin	A-055
Mair, Kerstin	B-078
Male, Viki	
Malmberg, Karl-Johan	A-080, A-092, A-103, A-116, A-105, B-064, B-081, B-094, B-114
Maltais, Anna-Karin	A-051, A-060
Mancini, Andrew	
Mandry, Maximilian	B-063
Manyseva, Ana	
Marquardt, Nicole	A-012, B-019, B-020, B-102
Marsal, Claire	A-007, B-014, B-016
Martin, Karen	
Matson, Anders	A-072, B-077, B-097
Matthys, Patrick	
Maucourant, Christopher	A-054, B-066
Maurer, Stefanie	A-077
Mayer, Corinna	B-076
McCulloch, Timothy	B-015
McMullen, Timothy	A-035
Meinke, Stephan	B-018
Melen, Geir Christian*	
Melsen, Janine E.	B-075, B-079
Menegatii, Sara	
Mensching, Leonore	B-092
Merino, Aimee	A-073
Michael, Melina	
Michaëlsson, Jakob	A-012, B-017, B-019, B-020, B-096, B-102
Miller, Jeffrey S.	A-052, A-053, A-062, A-065, A-072, A-073, A-078, A-079, A-109, A-112, B-044, B-049
Minguela, Alfredo	A-037, A-038
Mjösberg, Jenny	B-020, B-102
Moffett, Ashley	B-009
Mohammad, Dara	A-123, A-127

PARTICIPANT	POSTER
Mok, Adley CH	B-085
Momayyezi, Pouria	A-080, B-013
Montaner, Luis	
Morrison, Tasha	B-089
Morvan, Maelig	A-066
Mujal, Adriana	B-082, B-089, B-090
Mundy-Bosse, Bethany	A-098, A-004, B-079, B-083
Muntasell, Aura	B-111, A-107
Murali Shankar, Nivedha	B-065
Murin, Charles Daniel	B-124
Mustjoki, Satu	A-059, A-068, A-070, A-084
Myers, Jacob	A-052, B-049
Möker, Nina	A-087, A-121, A-125
Naeimi Kararoudi, Meisam	A-055, A-119, B-052, B-125
Nakkula, Robin	A-044
Narni-Mancinelli, Emilie	A-026
Natasha, Fariha	B-038
Nath, Pulak	A-106
Nattermann, Jacob	
Nayak, Indrani	B-041
Nersesian, Sarah	A-129, B-072
Netskar, Herman	B-064
Neulen, Marie-Luise	
Niehrs, Annika	A-015, B-006, B-067
Niemann, Jens	B-087
Norman, Paul	B-103
Nygren, Petra	A-059, A-068, A-084
Nygaard, Inez	
O'Dwyer, Michael	
O'Shea, John	
O'Sullivan, Timothy	A-035, B-119
Oei, Vincent Yi Sheng*	
Oja, Anna	A-082, A-096
Ohri, Rachit*	
Oliveira de Vasconcelos, Renata	B-120
Ollame-Omvane, Emilie	A-086, A-100

PARTICIPANT	POSTER
Oltz, Eugene	
Olweus, Johanna*	
Orange, Jordan	
Owyong, Mark	A-031, B-090, B-115
Ozcan, Oyku	B-127
Pahl, Jens	A-029
Palacios, Daniel	B-013
Pamukcu Suvari, Cevriye	
Papaioannou, Sophia	B-007
Park, Jeehun	B-004
Park, Kyung-Soon	A-043, B-047
Partensky, Peretz	A-077
Patey, Emma	B-067
Patterson, Chloe	B-023
Peng, Mingwen	
Peng, Hui	B-005, B-036, B-045
Peppa, Dimitra	A-063, B-040
Pereira, Marcelo	A-119, A-005
Perinetti Casoni, Giovanna	B-113
Pfefferle, Aline	A-092, B-064
Pete, Ellen Sofie	
Pfeifer Serrahima, Jordi	A-022, A-048
Philips, Rachael	B-089, B-130
Phung, Gwen	A-053, A-078, B-077
Pi, Ruoxi	A-115, B-098
Piersma, Sytse	A-088
Pires Bonfanti, Amanda	B-122
Pollmann, Sylvie	
Ponnurangam, Aparna	A-033
Preechanukul, Anucha	B-003
Preston, Hannah	A-002
Prüfer, Maren	A-022
Puga Yung, Gisella	B-042, B-095
Rackwitz, Wiebke	A-016, A-020

PARTICIPANT	POSTER
Rafei, Hind	A-011, A-018, A-018, A-074, A-099, B-107
Rahman, Mohammad Arif	A-001
Rajagopalan, Sumati	B-048, B-053
Raulet, David	A-118, B-033
Razmara, Aryana	A-006
Rebuffet, Lucas	
Reeves, R. Keith	B-006, B-068
Reggiani, Francesca	A-049
Reilly, Hazel	A-007, B-014, B-016
Reindl, Lisa Marie	A-090
Reis Galvao, Daniela	B-042
Renner, Alexander	A-023
Rettman, Pauline	B-043
Reyburn, Hugh	
Rezvani, Katy	A-011, A-018, A-074, A-099, B-107
Rogich, Allison	
Rolin, Camille	A-122
Romagnani, Chiara	A-008, B-002, B-030, B-063
Romee, Rizwan	A-059
Ross, Patrick	B-057, B-124
Rossi, Gustavo R.	A-091, B-015
Rubina, Anzelika	B-071
Ruiz-Lorente, Inmaculada	A-037, A-038
Ruppel, Katharina	A-017
Russick, Jules	A-104, B-067
Rødahl, Inga Elisabeth	B-019
Rødsten, Lise*	
Sackey, Sarah	A-115, B-098
Santosa, Endi	A-031, B-030, B-082, B-090
Sanz Ortega, Laura	A-013
Satter, Lisa Forbes	
Schafer, Jolie	
Scheer, Sebastian	B-061
Schenk, Robin	A-003, B-129
Schindler, Katharina	A-024
Schlueter, Juliane	A-027

PARTICIPANT	POSTER
Schmid, Kevin	A-003, B-129
Schmiedel, Dominik	A-017, A-023, A-097, B-032
Schultz, Ursula	
Seebach, Jörg Dieter	B-042, B-095
Serafini, Nicolas	
Serger, Clara	B-028
Shane, Hillary	
Shanley, Mayra	A-011, A-018, A-074, A-099, B-107
Sharkey, Andrew	B-009, B-056
Sheffer, Michal	A-059, A-083
Shemesh, Avishai	B-121
Sheppard, Sam	A-031, B-116
Shrestha, Rejeena	B-107
Silla, Lucia	
Sim, Malcolm	B-048
Sitnicka Quinn, Ewa	B-039, B-114, B-118
Smits, Evelien	A-047, A-108, A-128, B-084
Sohlberg, Ebba	B-081
Sohn, Stacey	B-034
Sommer, Samantha	B-128
Souza-Fonseca-Guimaraes, Fernando	A-091, B-015
Srpan, Katja	A-031, A-089, B-116
Stanton, Richard J.	A-002, B-071
Stojanovic, Ana	B-007, B-059, B-060
Strunz, Benedikt	B-006
Sudworth, Amanda	
Sun, Joseph C.	A-031, B-025, B-030, B-082, B-089, B-090, B-115, B-116, B-123
Sunwoo, John	A-117
Szabo, Edina	A-103, B-094
Sætersmoen, Michelle*	A-105
Tan, C. Sabrina	B-012
Thorén, Fredrik B	A-081, B-108, B-109
Torralba Raga, Lamberto Javier	A-105
Tran, Jennifer	B-055
Tran, Thao	B-095

PARTICIPANT	POSTER
Trenkner, Timo	B-100
Tundo, Sofia	B-028
Uhlig, Julia	A-050
Uhrberg, Markus	B-110, A-130
Ullrich, Evelyn	A-027, A-087, A-090
Ulriksen, Emilie S.	
Vales-Gomez, Mar*	
van Audenaerde, Jonas	A-047, A-108, A-128, B-084
van Hees, Els	A-019
van den Eynde, Astrid	A-047, A-108, A-128, B-084
van de Velde, Helgi*	
Vankayalapati, Krishna	
Vargas-Hernandez, Alexander	
Verhezen, Tias	A-047, A-108, A-128, B-084
Verneris, Michael	
Vick, Sarah	B-029
Vidal Manrique, Marcos	A-061, A-071
Vilches-Ruiz, Carlos	B-111
Vincenti, Marianna	A-103, B-094
Virone-Oddos, Angela	A-069
Vivier, Eric	A-026, A-069, B-045
Vo, Dang Nghiem	B-039, B-114
Vosshenrich, Christian	
Vu Van, Dana	A-076
Waggoner, Stephen N.	B-051, B-112
Wagner, Arnika K.	A-123, B-018, B-117
Wahlen, Sigrid	B-088, B-113
Walcheck, Bruce	A-072, B-077, B-097
Walter, Lutz	B-093, A-130
Walzer, Thierry	
Wang, Eddie	A-002, B-071
Wang, Xi	B-104
Watzl, Carsten	A-033, B-087, B-117
Weigand, Luise	
Weiss, Lea	B-081

PARTICIPANT	POSTER
Wels, Winfried S.	A-016, A-020, A-022, A-048, A-090
Westhaver, Lauren	A-129, B-072
Wiiger, Merete T	B-094
Wild, Nicole	A-012, B-020, B-102
Wilson, Jamie	
Witalisz-Siepracka, Agnieszka	A-030
Witt-Mulder, Kristina	A-116
Wolf, Asia-Sophia	
Wu, Chuanfeng	
Wu, Yunjie	B-106
Wöhr, Anne	B-109
Yamamae, Yui	B-058
Yee, Samantha	
Yokoyama, Wayne	A-088
Yousefi, Sascha	
Youssef, Youssef	A-004, B-083
Yu, Jianhua	
Yu, Minghang	B-104
Zecher, Britta	A-015
Zhang, Chenyu	B-033
Zhang, Congcong	A-048, A-121
Zhang, Yu	A-028
Zhu, Huang	
Zorko, Nicholas	A-052, A-053, A-062, A-078
Önfelt, Björn	A-080, B-069, B-117, B-127
Øynebråten, Inger	

*Clinical day only

NOTES


© SCIENCE SHAPED
NK2023
Sept 26-29 · OSLO